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Tileinkað Unni minni 
To my wife, Unnur 
 
  It’s the same with every career and life decision. You just have to keep 
driving down the road.  
  It’s going to bend and curve and you’ll speed up and slow down, but the 
road keeps going … 
Ellen DeGeneres 
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ABSTRACT 
Aims: The overall aim of this thesis was to increase knowledge about late-
life behavior variant frontotemporal dementia (bvFTD). One aim was to 
estimate the prevalence of bvFTD among older adults and to determine the 
agreement between different bvFTD criteria. Further aims were to study the 
correlation between bvFTD and frontal lobe atrophy (on CT) and to explore 
non-genetic risk factors and mortality in bvFTD among older adults. 
Methods: Population-based samples of 70 to 95-year-olds (N=2404) from 
Gothenburg, Sweden, underwent neuropsychiatric examinations and key 
informant interviews performed by neuropsychiatrists or psychiatric research 
nurses in 1986-2001. A subset (n=1074) underwent CT of the brain. BvFTD 
was diagnosed according to the International bvFTD Criteria Consortium 
(FTDC) and according to two other bvFTD criteria sets (FTLD-CC and 
LMRC). An exploratory nested case-control study examined potential risk 
factors among bvFTD cases, one control group without dementia and one 
with non-FTD dementia according to DSM-III-R. Mortality associated with 
bvFTD was compared to mortality among comparison groups with non-FTD 
dementia (DSM-III-R) and no dementia. 
Results: The prevalence of bvFTD varied between 0.2-0.5% at age 70-79, 
between 2.5-3.6% at age 80-89, and between 1.7-2.2% at age 90-95. To a 
large extent, different FTD criteria captured different individuals. Among 
those with bvFTD, 80% had frontal lobe atrophy on CT, compared to 9% of 
those without bvFTD. Alcohol abuse, stroke/TIA, head trauma, 
hypothyroidism, and being divorced were associated with increased odds of 
bvFTD. A diagnosis of bvFTD was associated with higher risk of death than 
a diagnosis of non-FTD dementias, especially among the oldest old.  
vi 
Conclusions: The findings suggest that bvFTD is more prevalent among 
older adults than previously supposed. The findings on risk factors have 
implications for future studies into the etiology of bvFTD, and ultimately, for 
prevention. Finally, it is important that clinicians are aware of this diagnosis 
among older adults, as it associated with a more aggressive course than other 
late-life dementias. 
Keywords: Frontotemporal dementia, older adults, prevalence, risk factor, 
mortality 
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SAMMANFATTNING PÅ SVENSKA 
Frontallobsdemens (FLD) är en plågsam, obotlig och dödlig demenssjukdom 
som anses drabba främst individer i åldrarna 40-65, men eventuell förekomst 
av denna sjukdom hos äldre individer (>70 år) har hittills inte undersökts på 
ett utförligt sätt. FLD orsakar en långsam försämring av högre intellektuella 
funktioner, speciellt de som är viktiga för omdöme och förmågan att 
upprätthålla sociala relationer. Det är för närvarande en vanlig uppfattning att 
frontallobsdemens är ytterst sällsynt hos äldre. Det finns dock indikationer 
om att FLD kan vara betydligt vanligare bland äldre än man hittills trott. 
Patienter som drabbas av FLD kan gå oupptäckta under en lång tid, då 
anhöriga och andra i patientens omgivning inte förknippar symptomen med 
en demenssjukdom, utan man försöker förgäves hitta någon annan förklaring 
till patientens ändrade beteende. Det är även svårt för läkare att ställa 
diagnosen, speciellt om man inte förväntar sig att träffa på denna sjukdom 
hos en äldre individ. Behandling av FLD skiljer sig även från behandling av 
andra demenssjukdomar, vilket är ett ytterligare skäl till att skärpa 
diagnostiken i denna utsatta grupp.  
Denna studie undersökte förekomsten och dödligheten av FLD i ett 
representativt befolkningsurval av 70–95-åringar från Göteborg. Alla 
deltagare genomgick identiska neuropsykiatriska undersökningar. Intervjuer 
gjordes med nära anhöriga eller vårdgivare till den undersökte. Dessa gav 
information om symtom som förekommer vid FLD och andra 
demenssjukdomar (såsom Alzheimers sjukdom). Intervjuerna gav också 
information om personens ålder vid insjuknandet och förloppet av dessa 
symtom. Detta gjorde oss möjligt att särskilja FLD från andra 
demenssjukdomar.  
I denna studie var frontallobsdemens vanligare bland äldre än tidigare trott 
(nästan 4% av alla 80-89-åringar var drabbade). Alkoholmissbruk, slaganfall, 
skallskador, hypotyreos (låg ämnesomsättning), och att vara frånskild var 
förknippade med ökad risk för FLD. FLD visade sig förkorta livet avsevärt, 
även mer än andra demenssjukdomar, särskilt bland de allra äldsta. 
Dessa resultat har också betydelse för framtida studier angående uppkomsten 
av FLD, och för att kunna etablera effektiva förebyggande åtgärder.  
Dessutom är det viktigt att öka medvetenheten om denna sjukdom, eftersom 
FLD är förknippad med stort lidande och utgör en svår börda för anhöriga 
och vårdpersonal, samt att den förkortar livet hos den drabbade även mer än 
andra demenssjukdomar hos äldre. 
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ÚTDRÁTTUR 
Framheilabilun (frontotemporal dementia) er ólæknandi sjúkdómur sem 
veldur heilabilun og leiðir óhjákvæmilega til dauða. Framheilabilun veldur 
hægri hrörnun á dómgreind, samkennd og félagslegri færni. Á fyrstu stigum 
sjúkdómsins getur því verið vandasamt að átta sig á því að um heilabilun sé 
að ræða. Sjúklingurinn hagar sér oft mjög afbrigðilega, en minnið og önnur 
vitræn geta er nánast óskert. Nánustu ættingjar og aðrir í umhverfi 
sjúklingsins  tengja því ekki einkennin við heilabilun, og  reyna árangurslaust 
að finna einhverja skýringu á breyttri hegðun sjúklingsins. Það er einnig erfitt 
fyrir lækna að greina þennan sjúkdóm á fyrstu stigum. Meðhöndlun á 
framheilabilun er frábrugðin meðferð á öðrum heilasjúkdómum og er því enn 
frekar ástæða til að bæta greiningu á þessum sjúkdómi. Fram til þessa hefur 
verið talið, að framheilabilun komi fyrst og fremst fram hjá einstaklingum á 
aldrinum 40-65 ára, og að framheilabilun sé mjög sjaldgæf eftir sjötugt. Þessi 
rannsókn kannaði tíðni, áhættuþætti og dánartíðni framheilabilunar meðal 
aldraða einstaklinga. 
Rannsóknirnar, sem kynntar eru í þessari ritgerð, voru gerðar á úrtaki meðal 
einstaklinga 70-95 ára í Gautaborg, Svíþjóð. Allir þátttakendur fóru í ýtarlega 
læknisskoðun og tekin voru greiningarviðtöl við nána aðstandendur. Með 
þessum athugunum var hægt að greina einkenni og framvindu heilabilunar, 
bæði framheilabilunar og annarra sjúkdóma, sem valda heilabilun (t.d. 
Alzheimers-sjúkdómur).  
Í þessari rannsókn kom í ljós, að framheilabilun meðal aldaðra var algengari 
en áður var talið (næstum 4% af öllum 80-89 ára voru greindir með 
framheilabilun). Framheilabilun reyndist  einnig leiða hraðar til dauða en 
aðrir sjúkdómar, sem valda heilabilun. Skv. þessari rannsókn komu einnig 
fram eftirfarandi áhættuþættir fyrir framheilabilun: misnotkun áfengis, 
heilablóðföll, höfuðáverkar, vanstarfsemi skjaldkirtils og að vera fráskilin(n). 
Rannóknir á áhættuþáttum eru mikilvægar til að greina orsakir 
framheilabilunar, og til að finna viðeigandi fyrirbyggjandi ráðstafanir.  
Að lokum, þá er mikilvægt að vekja athygli á þessum sjúkdómi, því hann 
leggur alvarlegar byrðar á herðar aðstandenda og styttir líf sjúklinga 
umtalsvert, jafnvel meira en aðrar tegundir heilabilunar. 
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INTRODUCTION 
Personality, emotions, language, the capability for complex social 
interactions and to anticipate future consequences of present actions; all are 
dependent on the continuous and proper function of the frontal lobes and 
associated circuits. It is therefore not surprising that selective degeneration of 
the frontal lobes can have devastating consequences, not only for those 
affected, but also for their families. Frontotemporal dementia (FTD) is a 
neurodegenerative disorder with circumscribed degeneration of the frontal 
lobes and anterior temporal lobes
1
. The Czech neuropsychiatrist Arnold Pick 
first described this type of degeneration in 1892
2
, but it still remained 
relatively obscure for almost a century. In the last three decades, interest for 
frontotemporal dementia (FTD) has increased substantially, as it has become 
recognized that FTD is the second most common neurodegenerative dementia 
among individuals under the age of 65
3
.  However, FTD is still believed to be 
rare among older adults, and epidemiological aspects have not been 
extensively explored, and there is a paucity of population-based studies on 
FTD. Few prevalence estimates exist among the older adults and the 
influence of different criteria on the prevalence of FTD is unclear. About 
50% of individuals diagnosed with FTD have no family history and are 
considered to be sporadic cases
4
, but risk factors for non-genetic FTD have 
not been extensively studied, especially among older adults. Furthermore, as 
life expectancy in the Western world is increasing, an increasing number of 
older adults may be diagnosed with FTD. Accurate mortality estimates of 
FTD are therefore crucial, not only for those afflicted with FTD, but also for 
relatives, caregivers and health care providers.  
Historical background 
During the first eighty years of the twentieth century, the only known form of 
frontotemporal dementia (FTD) was Pick’s disease. Arnold Pick (1851-1924) 
was a neuropsychiatrist working in Prague, who in 1892 wrote a case report 
describing a 71-year-old man with progressive dementia with unusually 
prominent aphasia. Autopsy revealed cortical atrophy, primarily of the left 
temporal lobe, with no focal lesions 
2
. Previously, dementia had been thought 
to be caused by diffuse degradation of mental abilities 
5, and  Pick’s major 
contribution to neuroscience was to associate dementia with macroscopic 
focal cortical atrophy
6
. However, it was Alois Alzheimer (1864-1915), who 
first described what subsequently became known as Pick cells and Pick 
bodies
7
. Pick's bodies are argyrophilic inclusions within neurons and Pick 
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cells are neurons swollen with argyrophilic material. The correlation between 
the clinical syndrome and the pathology was determined in the 1920's, with 
Onari and Spatz introducing the eponym Pick’s disease for this disorder 8. 
Patients with autopsy findings of Pick bodies and Pick cells were diagnosed 
as having had typical Pick's disease 
9
. Patients with frontal and/or temporal 
atrophy but without the typical microscopic findings were diagnosed as 
"atypical Pick's disease". During the twentieth century Pick's disease was 
considered quite rare and sometimes Pick's disease was lumped together with 
Alzheimer’s disease (AD) as Pick-Alzheimer spectrum10, 11. 
Although many researchers contributed to an increased understanding of 
Pick's disease during the first part of the twentieth century
11-17
, a major 
breakthrough came in the 1970's when the Lund dementia research group 
noted a number of dementia cases that presented with frontal symptoms, but 
had neuropathological findings that were not consistent with either Pick’s 
disease type or Alzheimer disease 
18
.  These patients had substantial clinical 
symptoms, but on a macroscopic level the brains showed little frontal atrophy 
in most cases. The microscopic findings were mild to vague, almost similar 
to artifacts
18
. The first study published with these findings was in 1977 
19
, and 
the first international conference on FTD was held as a satellite symposium 
of the tenth International Congress of Neuropathology
18, 20, 21
. Neary et al. 
described independently in 1988 a "dementia of the frontal lobe type" from a 
centre in Manchester, England
22
, and Knopman et al.  in 1990 published a 
paper describing "dementia lacking distinctive histology" 
23
.  
The first clinical and neuropathological criteria for FTD came in 1994, when 
the research groups in Lund and Manchester published clinical and 
pathological criteria for FTD
1
, and substantially revised FTD criteria were 
then published in 1998
24
 and in 2011
25
.  
During the past 15 years the research on FTD has expanded rapidly
18
 with 
progress in many fields, but particularly with regards to neuropathology
26, 27
 
and genetics
28
, some aspects of which will be covered in the following 
sections. 
 
Clinical features of FTD 
The major presenting feature of FTD is a profound change in personal and 
social conduct coupled with a deterioration of frontal lobe functioning (e.g. 
executive function) 
29
. This change in frontal lobe functioning may initially 
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not be apparent except on neuropsychological testing. However, the change 
in personality is almost invariably jarring to close relatives and friends, and is 
not related to pre-morbid personality
30
. The onset of symptoms is typically 
insidious, and therefore often interpreted as being caused by psychiatric 
illness, such as an affective disorder 
29, 31
Also, psychiatric manifestations 
often occur early, with dysthymia being present in one third of patients with 
FTD at initial presentation
32
, and anxiety being more common in FTD than in 
AD
33
. 
FTD patients are strikingly unaware of the change in their personality and 
behavior, but may admit that they are feeling ill
34
, often without being able to 
specify that more exactly. As individuals with FTD have limited insight into 
their illness, it becomes crucial to have a close informant, e.g. a close family 
member, in order to make the correct diagnosis
3
. 
The frontal lobe deficits are often revealed in a social context as 
inappropriate behavior becomes troubling to the environment. The FTD 
patient’s behavior becomes marked by mental inflexibility and failure to 
adapt to new social situations, and there may be incidents of inappropriate 
joking or touching, and not respecting interpersonal space. Some patients are 
restless and overactive
31
, but some are most often inactive and seem to lack 
motivation for previously important activities
34
. Some patients have 
alternating periods of hyperactivity and inactivity
34
.  
FTD patients are more likely than patients with Alzheimer’s disease to come 
into contact with the judicial system
35
. Some patients experience a 
particularly malignant combination of losing moral sense and empathy, as 
well as developing disinhibited and compulsive behavior
36, 37
.  This acquired 
sociopathy can lead to unacceptable behavior such as traffic violations, 
physical assaults and unsolicited sexual acts
38
. 
FTD patients also often exhibit altered eating patterns and changes in appetite 
or food preference; in early stages this usually takes the form of increased 
appetite and table manners, e.g. taking food first, and overeating where that is 
socially inappropriate. This may also be accompanied by excessive alcohol 
consumption
39
. 
Emotional blunting is also a characteristic feature of FTD
40
, often 
accompanied by loss of empathy and emotional unconcern
41
, a common early 
feature being loss of interest in one’s family42. 
Repetitive and stereotyped behaviors may be seen in patients with FTD, e.g. 
simple mannerisms, repetitive motor acts or hand-clapping. There may also 
be more complex acts, such as repeating phrases or parts of sentences 
(palilalia), repeating another person’s words (echolalia) or repeatedly singing 
the same song
34
. Furthermore, a patient with FTD may exhibit utilization 
behavior
43
, i.e. if the patient sees an object, he may start to use that object, 
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even if that action is inappropriate. For example, if presented with a pen, the 
patient may start writing on any nearby surface, e.g. a table. 
Although memory dysfunction may not be apparent in the early stages of 
FTD, neuropsychological testing may reveal impairments in episodic 
memory, even early in the course of the disease
44
. However, visuospatial 
functions are often spared in the initial stages 
3
. 
The above description of symptoms refers to the variant of FTD that is 
known as behavioral FTD (bvFTD), which is the most common presentation 
of FTD (nearly 60% of cases)
4
. However, FTD may also present with decline 
in language skills, which is known as primary progressive aphasia
45
. This 
language variant is further subdivided into semantic dementia, progressive 
non-fluent aphasia and logopenic progressive aphasia
24, 45, 46
, according to the 
predominant pattern of language disturbance
40
.  
Ultimately, all individuals develop a global dementia, regardless of initial 
phenotype
47
. 
 
Genetics of FTD 
A family history of FTD is present in 25–50% of cases, indicating a 
considerable genetic component
28
. The first reports of genetic 
mutations associated with FTD came in 1998
48-50
, when mutations in the 
microtubule-associated protein tau (MAPT) gene on chromosome 17 were 
identified in a number of families with FTD and Parkinsonism. It has 
subsequently become clear that FTD can be caused by several other 
mutations, the most common being progranulin (PGRN) 
51, 52
 and 
chromosome 9 open reading frame 72 (C9orf72) expansions 
53, 54
. Much rarer 
causes of FTD are mutations in the valosin-containing protein (VCP) gene 
55
 
and a mutation in the gene for charged multivesicular body protein 2B 
(CHMP2B) 
56
. 
A recent genome-wide association study among 3526 patients with FTD 
suggested that loci encompassing the major histocompatibility complex (on 
chromosome 6) and possibly lysosomal and autophagy pathways (on 
chromosome 11) are potentially involved in FTD 
57
. Furthermore, a genome-
wide exome array study that included 168 patients with FTD suggests that 
low-frequency coding variants with intermediate effect size may account for 
a significant fraction of the genetic susceptibility to FTD, but did not 
otherwise uncover any new associations 
58, 59
. 
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Neuropathology 
Unlike AD, the neuropathology associated with the clinical syndrome of FTD 
is heterogeneous, the common feature being a selective degeneration of the 
frontal and anterior temporal lobes 
60
. The current nomenclature uses the term 
“frontotemporal dementia” (FTD) to denote the clinical entity and 
“frontotemporal lobar degeneration” (FTLD) for the neuropathological 
condition. The classical histopathology of FTLD shows cortical neuronal 
loss, astrocytic gliosis and microvacuolation, most prominent in cortical 
layers II and III in the frontal and anterior temporal lobes
20, 61
.  
White matter changes are usually those of astocytic gliosis and myelin loss
21
. 
The white matter changes generally follow the affected cortical regions, but 
there may also be some white matter involvement in regions where the cortex 
is not affected 
62
. It still remains to be resolved if the white matter changes 
are a result of Wallerian degeneration per se, or if the changes are caused by 
a combination of direct pathology of the white matter and Wallerian 
degeneration
63, 64
. 
Immunohistochemistry has revealed several types of abnormal intracellular 
protein deposits in FTLD, and these inclusions have linkage with genetics 
and to some degree with clinical symptoms 
3
. The main neuropathological 
types of FTLD according to current classification are FTLD-tau, FTLD-TDP 
(types A-D), FTLD-UPS and FTLD-FUS (fused in sarcoma).  
There is a clear correspondence between genetic mutations and pathology, 
MAPT mutations leading to tau pathology, PGRN mutations leading mainly 
to FTLD-TDP pathology Type A, C9orf72 mutations to FTLD-TDP 
pathology Type B and CHMP2B to FTLD-UPS 
28
. The main 
histopathological subtypes associated with bvFTD are FTLD-tau, FTLD-TDP 
and FTLD-FUS
28
. 
FTD Criteria 
The need for consensus on clinical and neuropathological criteria became 
evident as more studies were published from different centers during the late 
1980’s and early 1990’s. In 1994, the research groups in Lund and 
Manchester published clinical and pathological criteria for FTD 
1
, the Lund-
Manchester research criteria (LMRC). These criteria include three 
frontotemporal dementia symptom constellations: (1) behavioral symptoms, 
(2) affective symptoms and (3) symptoms of a speech disorder (table). The 
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onset has to be insidious and the course invariably progressive. However, the 
criteria do not describe how many symptoms or symptom constellations have 
to be present for a diagnosis. A re-working of the Lund-Manchester Research 
Criteria (LMRC) was published in 1998 with the Consensus criteria on 
frontotemporal lobar degeneration (FTLD) 
24
. These criteria included even 
the categories of semantic dementia and progressive aphasia. However, the 
1998 criteria came to be considered to be too rigid for clinical and research 
purposes
65
.
 
In 2011, the International Behavioral Variant FTD Criteria 
Consortium (FTDC) proposed revised criteria
25
.
 
These three sets of 
diagnostic criteria include different combinations of impairments in social 
and emotional abilities. According to earlier terminology, FTD with 
behavioural symptoms was called frontal variant FTD (fvFTD) 
66
. For the 
sake of clarity, only the term “bvFTD” will be used in this dissertation. 
 
Table 1. The Lund-Manchester Research Criteria for clinical diagnosis of 
frontotemporal dementia 
1
. 
Core diagnostic features  
Behavioral disorder 
* Insidious onset and slow progression 
* Early loss of personal awareness (neglect of personal hygiene) 
* Early loss of social awareness (lack of social tact) 
* Early signs of disinhibition  
* Mental rigidity and inflexibility 
* Hyperorality  
* Stereotyped and perservative behavior  
* Utilization behavior  
* Choreo-athetosis 
* Distractibility, impulsivity, and impersistence 
* Early loss of insight  
Affective symptoms 
* Depression, anxiety, excessive sentimentality 
* Hypochondriasis, bizarre somatic preoccupation  
* Emotional unconcern  
* Amimia (inertia, aspontaneity) 
Speech disorder 
* Progressive reduction of speech  
* Stereotypy of speech  
* Echolalia and perseveration 
* Late mutism 
 
Thorsteinn B. Gislason 
7 
 
Table 2. Diagnostic exclusion features in the Lund-Manchester Research 
Criteria for clinical diagnosis of frontotemporal dementia 
1
. 
Diagnostic exclusion features  
* Abrupt onset with ictal events 
* Head trauma related to onset 
* Early severe amnesia 
* Early spatial disorientation 
* Early severe apraxia 
* Logoclonic speech with rapid loss of train of thought 
* Myoclonus 
* Cortical bulbar and spinal deficits 
* Cerebellar ataxia 
* Choreo-athetosis 
 
 
Table 3. The clinical diagnostic features of FTD: Clinical profile from the 
Consensus criteria on frontotemporal lobar degeneration (FTLD-CC) 
24
 
Core diagnostic features 
A. Insidious onset and gradual progression 
B. Early decline in social interpersonal conduct 
C. Early impairment in regulation of personal conduct 
D. Early emotional blunting 
E. Early loss of insight 
 
Historical and clinical exclusion features 
1. Abrupt onset with ictal events 
2. Head trauma related to onset 
3. Early, severe amnesia 
4. Spatial disorientation 
5. Logoclonic, festinant speech with loss of train of thought 
6. Myoclonus 
7. Corticospinal weakness 
8. Cerebellar ataxia 
9. Choreoathetosis 
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Table 4. International consensus criteria for behavioural variant FTD 
(FTDC)
25
. 
I. The following symptom must be present to meet criteria for bvFTD 
A. Shows progressive deterioration of behavior and/or cognition by observation or history (as provided by a knowledgeable informant). 
II. Possible bvFTD 
Three of the following behavioral/cognitive symptoms (A–F) must be present to meet criteria.  
Ascertainment requires that symptoms be persistent or recurrent, rather than single or rare events. 
A. Early behavioral disinhibition (one of the following symptoms): 
            A.1. Socially inappropriate behavior 
            A.2. Loss of manners or decorum 
            A.3. Impulsive, rash or careless actions 
B. Early apathy or inertia (one of the following symptoms): 
            B.1. Apathy 
            B.2. Inertia 
C. Early loss of sympathy or empathy (one of the following symptoms): 
            C.1. Diminished response to other people’s needs and feelings 
            C.2. Diminished social interest, interrelatedness or personal warmth 
D. Early perseverative, stereotyped or compulsive/ritualistic behavior (one of the following symptoms): 
            D.1. Simple repetitive movements 
            D.2. Complex, compulsive or ritualistic behaviors 
            D.3. Stereotypy of speech 
E. Hyperorality and dietary changes (one of the following symptoms): 
            E.1. Altered food preferences 
            E.2. Binge eating, increased consumption of alcohol or cigarettes 
            E.3. Oral exploration or consumption of inedible objects 
F. Neuropsychological profile: executive/generation deficits with relative sparing of memory and visuospatial functions (all of the following 
symptoms must be present): 
            F.1. Deficits in executive tasks 
            F.2. Relative sparing of episodic memory 
            F.3. Relative sparing of visuospatial skills 
III. Probable bvFTD 
All of the following symptoms (A–C) must be present to meet criteria. 
A. Meets criteria for possible bvFTD 
B. Exhibits significant functional decline (by caregiver report or as evidenced by Clinical Dementia Rating Scale or Functional Activities 
Questionnaire scores) 
C. Imaging results consistent with bvFTD [one of the following (C.1–C.2) must be present]: 
            C.1. Frontal and/or anterior temporal atrophy on MRI or CT 
            C.2. Frontal and/or anterior temporal hypoperfusion on PET or SPECT 
IV. Behavioural variant FTD with definite FTLD Pathology 
Criterion A and either criterion B or C must be present to meet criteria. 
    A. Meets criteria for possible or probable bvFTD 
    B. Histopathological evidence of FTLD on biopsy or at post-mortem 
    C. Presence of a known pathogenic mutation 
V. Exclusionary criteria for bvFTD 
Criteria A and B must be answered negatively for any bvFTD diagnosis. Criterion C can be positive for possible bvFTD but must be negative 
for probable bvFTD. 
    A. Pattern of deficits is better accounted for by other non-degenerative nervous system or   medical disorders 
    B. Behavioral disturbance is better accounted for by a psychiatric diagnosis 
    C. Biomarkers strongly indicative of Alzheimer’s disease or other neurodegenerative process 
 
 
Thorsteinn B. Gislason 
9 
 
Prevalence of FTD 
Population studies on FTD have usually been performed within a regional 
catchment area, using medical records or disease registers 
4
. Only a few have 
recruited individuals directly from the population
67, 68
. Prevalence estimates 
vary from 2/100 000 to 31/100 000
67-73
. Most studies have focused on the age 
group under age 65 and few population studies have examined 
epidemiological aspects of FTD in older adults. The prevalence is reported to 
be lower than one percent using LMRC or FTLD-CC in individuals above 
age 65 years
74-77
. However, these studies only included cases of FTD who 
also fulfilled criteria for global dementia, in which memory problems are 
mandatory. Thus, individuals with FTD who do not fulfill criteria for global 
dementia may remain undetected
42, 78
. Furthermore, key informant interviews 
(with close relatives and caregivers) were used in only two of these studies
74, 
77
. Key informant interviews are crucial to obtain retrospective information 
about early symptoms and course of symptoms, as these are necessary to 
differentiate bvFTD from other dementia disorders.  
While it has been suggested that FTD may be more common than previously 
supposed
40, 79, 80
, few previous studies have examined the prevalence of FTD 
in a wider range of ages among the elderly. Neither has the utility of different 
criteria been examined in elderly populations.  
 
Neuroimaging 
Most previous studies on neuroradiological findings in bvFTD have used 
MRI and consistently report cortical atrophy in the frontal and anterior 
temporal lobes
81, 82
. The frontal atrophy involves medial, dorsolateral and 
orbiotofrontal regions 
81
 and longitudinal studies have shown that the atrophy 
is progressive, especially in the medial frontal cortex
83-85
. Other cortical areas 
(i.e. parietal cortex) may also be involved, but usually to a lesser degree. 
Deep cortical gray matter structures (caudate nucleus, globus pallidus and 
nucleus accumbens) may also be affected in FTD
86
.  
 
Risk factors in FTD 
About 50% of individuals diagnosed with FTD have no family history and 
are considered to be sporadic cases 
87
. Only three previous case-control 
studies have examined non-genetic risk factors for FTD (table 1)
88-90
. These 
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studies recruited cases from patient samples. Two of the studies used controls 
without dementia and memory complaints.  One of these studies recruited 
controls from nursing homes and the other recruited controls from a general 
medical practice list
88, 90
. The third study used controls with non-FTD 
dementias recruited from the same Veterans Affairs medical center as the 
cases
89
. One study focused on the association of FTD and potential 
cardiovascular risk factors 
90
.  
The main finding in two of these studies was that head trauma was associated 
with increased risk of FTD 
88, 89
, while one study found an association with 
diabetes mellitus 
90
. Furthermore, two studies found trends for associations 
with thyroid disease
88, 90
, and one reported that cardiovascular disease was 
less common among bvFTD cases 
89
. 
 
Table 5. Previous case-control studies on non-genetic risk factors in 
frontotemporal dementia. 
 Controls Major 
findings 
Trends 
Rosso et al. 
2003 
88
 
No 
dementia 
Head 
trauma ↑ 
Hypothyroidism ↑ 
Kalkonde et 
al. 2012 
89
 
Non-FTD 
dementia 
Head 
trauma ↑ 
Cardiovascular 
diseases ↓ 
Golimstok et 
al. 2014 
90
 
No 
dementia 
Diabetes 
mellitus ↑ 
Hypothyroidism ↑ 
 
 
Furthermore, a study specifically exploring the relationship of head trauma 
and FTD, found that head trauma with extended loss of consciousness was 
more common among individuals with bvFTD than among normal controls
91
. 
Moreover, individuals with a language variant of FTD (semantic dementia) 
and a history of head trauma, had more behavioral problems than affected 
individuals without history of head trauma
91
. 
Mortality in FTD 
Although previously thought to be rare, FTD is increasingly being recognized 
among the older adults
80
. Furthermore, life expectancy in the Western world 
is increasing 
92
. Thus, it is to be expected that more elderly individuals will be 
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diagnosed with FTD. Accurate mortality estimates of FTD are therefore 
crucial, not only for those afflicted with FTD, but also for relatives, 
caregivers and health care providers. However, mortality in FTD has so far 
not been studied in elderly populations.  
Moreover, population studies of mortality of FTD are difficult to conduct, 
because FTD is relatively rare and the clinical presentation is heterogeneous 
4
. Thus, most previous studies on mortality are derived from specialist clinics 
or are based on retrospective information from neuropathological series
4
. 
Three-year mortality from clinical diagnosis of FTD ranges from 20 to 40% 
in studies from specialist clinics 
93-95
 and from 30 to 45% in neuropathology 
series
96-98
. Three-year mortality from symptom onset ranges from 5-10 % in 
clinical studies
93, 95
 and 10-15% in neuropathology series
97, 98
. Furthermore,  
ten-year mortality ranges from 75-95% in clinical studies 
93-95
 and 80-95% in 
neuropathology series 
96-98
, and from symptom onset from 45-75% in studies 
from specialist clinics 
93, 95
 and 50-75% in neuropathology series
97, 98
. 
 
The mean or median survival time from clinical diagnosis of FTD has been 
estimated to range from 3.0 to 6.2 years in clinical samples 
93-95
 and from 3.0 
to 4.2 years in neuropathological series 
97, 98
, and from symptom onset to 
death from 6.6 to 10.4 years in studies from specialist clinics 
93-95, 99-103
, and 
from 6.0 to 8.0 years in neuropathology series 
97, 104, 105
. Some studies suggest 
that individuals with FTD progress to death faster than individuals with 
Alzheimer’s disease (AD) 40, but other studies have found similar survival 
times in FTD and AD 
100
. The main causes of death in FTD according to 
previous studies are pneumonia, cardiovascular disorders and cachexia 
4, 100, 
106
. However, causes of death in FTD have not been extensively examined in 
population-based studies. 
 
Gender distribution 
Previous studies vary with regards to reports of the sex distribution in FTD; a 
study from Cambridgeshire 
69
 reported a five-fold higher prevalence among 
men and a study from Zuid-Holland reported an equal sex distribution 
71
. 
Other studies have reported a slight female preponderance
68, 73, 107
. 
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THE CURRENT STUDY OF FTD 
Aims   
The overall aim of this thesis was to increase knowledge about late-life 
behavior variant frontotemporal dementia (bvFTD) using a population-based 
setting in Gothenburg, Sweden. The specific aims were: 
1. To study the prevalence of frontal lobe syndrome and 
bvFTD using the Lund-Manchester research criteria 
(LMRC) in a representative sample of 85-year-olds. (Paper 
I). 
 
2. To examine the prevalence of bvFTD in population samples 
of 70-95-year-olds using three sets of criteria (the FTDC, the 
FTLD-CC and the LMRC; Paper II). 
 
3. To determine the agreement between these three FTD 
criteria sets (Paper II). 
 
4. To  study the correlation between bvFTD and the occurrence 
of frontal and/or temporal lobe atrophy on computerized 
tomography of the brain (Paper II). 
 
5. To perform an exploratory nested case-control study of 
possible risk factors among 70-95-year-olds diagnosed with 
bvFTD and two age- and sex-matched control groups 
derived from the same population, one with non-FTD 
dementia and one without (Paper III). 
 
6. To examine mortality associated with bvFTD in a 
population-based study among 70-95-year-olds and to 
compare mortality in bvFTD with mortality in non-FTD 
dementias and no dementia (Paper IV). 
 
7. To examine cause of death in bvFTD according to death 
certificates, and to determine if cause of death differed 
between bvFTD, non-FTD dementias and no dementia 
(Paper IV). 
 
Thorsteinn B. Gislason 
13 
 
SUBJECTS AND METHODS 
Between 1986 and 2001, studies on representative elderly populations in 
Gothenburg, Sweden were conducted using identical examinations (including 
neuropsychiatric examinations and key informant interviews) at each 
occasion
108
. The samples included the H85-study 
109
, the 95+study 
110
, the 
Prospective Population Study of Women (PPSW) 
111
 and the H70-study 
112
. 
All samples were systematically obtained from the Swedish population 
register based on birth dates, and included people living in private households 
and in residential care. An overview of the samples included in this study is 
shown in figure 1. 
Subjects 
H-85 participants 
In 1986-7, an effective sample of 783 85-year-olds was selected and a total of 
494 individuals (351 women and 143 men) agreed to participate (response 
rate 63%) 
109
. There were no differences between participants and non-
participants regarding sex, marital status, registration as psychiatric 
outpatients or inpatients, three-year mortality rate and institutionalization. 
Identical studies in this sample were conducted at ages 88 (n=260), 90 
(n=200) and 92 years (n=190)
113
.  
 
95+study participants 
In 1996-98, an effective sample of 529 95-year-olds was selected and a total 
of 338 individuals (263 women and 75 men) agreed to participate (response 
rate 64%). There were no significant differences between participants and 
non-participants regarding marital status and three-year mortality rate 
110
. 
 
PPSW participants 
In 1992-93, an effective sample of 837 women (aged 70, 74, 78 and 84) was 
selected and a total of 559 women (response rate 67%) agreed to take part 
(255 aged 70, 215 aged 74, 70 aged 78 and 19 aged 84) 
111, 114-116
. In 2000-
2001, 629 of the women were alive, and 439 (response rate 70%) agreed to 
participate in neuropsychiatric examinations (216 aged 78, 171 aged 82, 44 
aged 86 and 8 aged 92).  
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H-70 participants 
In 2000-01, an effective sample of 827 70-year-olds was selected and a total 
of 579 individuals (350 women and 229 men) agreed to participate (response 
rate 70%)
117
. There were no differences between participants and non-
participants regarding sex, marital status or previous outpatient or inpatient 
psychiatric care. Non-participants had higher five-year mortality rate than 
participants both among women (9.0% vs. 2.3% p<0.001) and among men 
(23.7% vs. 7.5%, p<0.001), as described previously
117
. 
 
 
Figure 1. Overview of samples included in this study (H-85, H-95+, PPSW, H-
70). 
Graph by Erik Joas 
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Sample in paper I 
In paper I, the sample of 494 85-year-olds (143 men, 351 women) described 
on page 13 (2
nd
 paragraph) was used and individuals without key informant 
interview were excluded, leaving an effective sample of 451 individuals (131 
men and 320 women). As key informant interviews were necessary to 
confirm or exclude the diagnosis of bvFTD, the final step in selecting study 
samples was to exclude those individuals that did not have a key informant 
interview. 
 
Merged sample in paper II 
 
In paper II, the data from the four studies described on pages 13-14 were 
merged, and 630 individuals without key informant interviews were 
excluded. This merged sample was stratified by ages 70-79, 80-89 and 90-95 
years (table 9). The proportion of women in this sample was high (80%), 
partly because the study included samples from the PPSW (exclusively 
women), and partly because of an oversampling of individuals above age 85 
years (who were predominantly women). 
 
Merged sample in paper III-IV 
In papers III-IV, the data from the four studies described on pages 13-14 
were also merged, resulting in a sample of 2404 individuals. Furthermore, 
630 individuals without key informant interview were excluded, resulting in 
a sample of 1774 individuals (388 men, 1386 women; 940 aged 70-79 years, 
470 aged 80-89 years and 364 aged 90-95 years). Response rates for the 
different studies in the merged sample varied from 63-70% 
118
. As discussed 
in the previous section, the proportion of women in this sample was high 
(80%). 
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Methods  
Neuropsychiatric examination 
Identical neuropsychiatric examinations and key informant interviews were 
used for all participants included in this study. The neuropsychiatric 
examinations were semi-structured and performed by trained 
neuropsychiatrists, except in 2000-2001 when they were performed by 
experienced psychiatric research nurses. The examinations included ratings 
of symptoms and signs common in dementia and a cognitive test battery
109
. 
Psychiatric symptoms and signs were rated with the Comprehensive 
Psychopathological Rating Scale
119
. Frontal lobe symptoms assessed included 
disinhibition, aggressiveness, hyperorality, hyperphagia, hypersexuality, 
perseverative or stereotypic behavior, utilization behavior, apathy, emotional 
bluntness and loss of empathy. Tests of cognitive function included 
assessments of recent and remote memory, orientation for time, place, person 
and situation, apraxia, constructional apraxia, ideational apraxia, ability to 
understand proverbs, ability to follow commands, finger agnosia, judgment, 
and language. The Mini Mental State Examination 
120
 Alzheimer’s disease 
Assessment Scale-cognitive subscale (ADAS-Cog)
121
, the Montgomery–
Åsberg Depression Rating Scale (MADRS)
122
 and a global rating of mental 
health were also performed in all studies. 
 
 
Self-report 
As a part of the neuropsychiatric examination, a modified medical history 
was completed, including questions about previous and current medical 
disorders (e.g. cardiovascular disorders, stroke, diabetes mellitus, cancer, 
surgery and fractures), previous and current mental disorders, current use of 
medication, occurrence of dementia in first-degree relatives, alcohol 
consumption and sleep. 
 
Key informant interviews 
The semi-structured telephone-interviews with key informants included 
questions about cognitive, emotional and behavioral symptoms, e.g. global 
changes in personality, memory, orientation, difficulties in finding way in 
familiar surroundings, intellectual ability, language, speech, motivation, 
disinhibition, emotional bluntness, suspiciousness and paranoid ideas, 
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depression, lachrymosity, anxiety and worries, irritability, aggressive 
behavior, performances in activities of daily living, and insight. Questions 
were asked about age at onset and course of symptoms
109
. The retrospective 
information from key informants was needed to elucidate early symptoms 
and course of symptom development. The data were collected blindly to any 
diagnostic aspects. 
 
Other sources of information 
Medical and psychiatric diagnoses were derived from self-reports, 
neuropsychiatric examinations, key informant interviews and data from the 
Swedish hospital discharge register. Since 1978, everybody admitted to a 
Swedish hospital are registered in a hospital-discharge system with diagnoses 
registered according to the International Statistical Classification of Diseases 
and Related Health Problems (ICD-8, ICD-9 or ICD-10) 
123-125
.  
Date and causes of death were obtained from the Swedish population register. 
This is a national register (The Swedish Health and Welfare Statistical 
Database for Cause of Death) that includes all individuals living in Sweden 
and Swedish citizens living abroad 
126
. The register is known to be complete 
regarding data on mortality and cause of death. 
 
Diagnostic procedures 
Diagnosis in paper I 
The Lund-Manchester research criteria (LMRC)
1
 include three 
frontotemporal dementia symptom constellations: (1) behavioral symptoms, 
(2) affective symptoms and (3) symptoms of a speech disorder. The onset has 
to be insidious and the course invariably progressive. The criteria do not 
describe in detail the required severity of the symptoms, or how many 
symptoms or symptom constellations have to be present for a diagnosis. 
Therefore,  an algorithm was constructed for the identification of FLS based 
on the core symptoms of FTD noted during the psychiatric examination and 
the close informant interview. The symptoms were selected to avoid 
misclassification with other disorders. Therefore, symptoms of language 
disturbance were not included, as language disturbance does not separate AD 
from FTD
127
. For a symptom to be classified as present it had to lead to 
significant disturbance. The symptoms were grouped into four clusters: (1) 
behavioral signs typical for FTD from the neuropsychiatric examination, (2) 
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behavioral symptoms typical for FTD from the informant interview, (3) 
affective symptoms typical for FTD from the neuropsychiatric examination 
and (4) affective symptoms typical for FTD from the informant interview. 
The individual symptoms selected in the different symptom constellations 
were based on the description in the LMRC, and are shown in table 6.  
 
Table 6. Symptoms and signs of frontal lobe dysfunction as defined by the 
Lund-Manchester Research Criteria. 
 
Behavioral signs from the neuropsychiatric interview 
 Loss of insight 
 Loss of social tact 
 Disinhibition 
 Hypersexuality 
 Hyperorality (2 items) 
 Perseverative or stereotypic behavior (2 items) 
 Utilization behavior 
 
Behavioral symptoms from the informant interview 
 Change in personality 
 Loss of insight 
 Impaired judgment 
 Lack of social tact 
 Disinhibition 
 Inappropriate jocularity 
 
Affective signs from the neuropsychiatric examination 
 Apathy (2 items) 
 Emotional blunting 
 
Affective symptoms from the informant interview 
 Aspontaneity (2 items) 
 Emotional blunting (3 items) 
 Emotional unconcern and indifference (3 items) 
 Neglect of grooming 
 Neglect of hygiene 
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Diagnosis of FLS in Paper I 
The algorithm for the identification of FLS is described in figure 2. An 
individual had to have a minimum number of symptoms in both the 
neuropsychiatric examination and the informant interview, and always a 
minimum number of behavioral symptoms. Thus if an individual had two or 
more behavioral symptoms in the neuropsychiatric examination, he had to 
have at least three behavioral symptoms in the informant interview in order to 
be classified as having FLS. If there were less than two behavioral symptoms 
in the neuropsychiatric examination, it was required that at least two affective 
symptoms in the neuropsychiatric examination should be present and at least 
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three behavioral symptoms in the informant interview. If an individual had 
two (or more) behavioral symptoms in the neuropsychiatric examination, but 
fewer than three behavioral symptoms in the informant interview, at least 
three affective symptoms had to be present in the informant interview for a 
classification of FLS (fig. 2). 
 
 
 
Figure 2. Diagnostic algorithm for frontal lobe syndrome (FLS) 
based on the Lund-Manchester Research Criteria (LMRC).  
 
 
 
Gislason et al. J Neurol Neurosurg Psych 2003;74:867-71 
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Diagnosis of bvFTD in Paper I 
Behavioral variant frontotemporal dementia (bvFTD) was diagnosed in 
subjects with FLS who presented with only frontal lobe symptoms or with 
behavioural symptoms that clearly preceded (by two years or more) memory 
loss or other cognitive signs, such as agnosia or apraxia. The diagnosis of 
bvFTD could not be applied in the presence of early onset of memory 
problems, early spatial disorientation, early apraxia, vascular dementia, 
chronic alcoholism and schizophrenia (exclusion criteria shown in figure 3). 
 
Figure 3. Diagnostic algorithm for behavioral variant frontotemporal 
dementia (bvFTD) according to the Lund-Manchester Reseach 
Criteria (LMRC). 
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Diagnosis of bvFTD in Papers II-IV 
The FTDC criteria of bvFTD define five symptom clusters for the diagnosis 
of possible bvFTD: disinhibition, perseveration, apathy, lack of empathy and 
hyperorality. Furthermore the FTDC criteria define a sixth cluster, executive 
dysfunction. Symptoms from at least three clusters need to be present for a 
diagnosis
25
. The algorithm based on the FTDC is described in figure 4, 
describing the use of the clinical symptom constellations from the FTDC. 
 
Figure 4. Algorithm for diagnosis of bvFTD from International 
consensus criteria for behavioral variant FTD (FTDC). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Gislason et al. Alzheimers Dement. 2015;11:425-33 
Hyperorality, 
dietary change 
Stereotyped or 
compulsive 
Apathy or 
inertia 
Behavioral 
disinhibition 
Loss of 
empathy 
 
 Symptoms from at least  
3 clusters 
 
 Course compatible with bvFTD?  
bvFrontotemporal dementia 
Exclusion criteria: 
# Early severe memory loss  
# Early spatial or temporal disorientation      
# Stroke in relation to FTD-symptoms 
# Medical disorders capable of inducing frontal deficits 
# Major depressive disorder  
# Schizophrenia  
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Figure 5. Algorithm for diagnosis of bvFTD from FTLD consensus 
criteria (FTLD-CC). 
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The FTDC do not include early spatial or temporal disorientation as an 
exclusion feature, but it was added here as an exclusion feature in order to 
better separate bvFTD from non-FTD dementia in this population with high 
prevalence of non-FTD dementia. 
The 1998 consensus criteria (FTLD-CC) of bvFTD define four frontal lobe 
symptom clusters: impaired social conduct, impaired personal conduct, 
emotional blunting and loss of insight 
24
. For a diagnosis of bvFTD, it is 
mandatory to have symptoms from all symptom clusters. The algorithm 
based on the FTLD-CC is described in figure 5.  
 
Exclusion criteria: 
# Stroke in relation to FTD-symptoms 
# Early severe memory loss  
# Early spatial or temporal disorientation  
# Major depressive disorder  
# Parkinson’s disease  
# Schizophrenia 
 Course compatible with bvFTD?  
bvFrontotemporal dementia 
 At least 1 symptom from  
each cluster 
 
Impaired social 
conduct 
Impaired personal 
conduct 
Emotional 
blunting 
Loss of insight 
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Figure 6. Algorithm for diagnosis of bvFTD from Lund-Manchester 
Research Criteria (LMRC). 
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As previously described (p. 20), the LMRC define three clusters of frontal 
lobe symptoms (behavioral, affective and language)
1
. Language disturbance 
is not included as a symptom in FTDC and FTLD-CC criteria for bvFTD. To 
make criteria comparable with FTDC and FTLD-CC criteria, we therefore 
only used the first two clusters from LMRC to define a ‘LMRC bvFTD’. The 
algorithm based on the LMRC is described in figure 6.  
The first step in the diagnostic process was to select individuals fulfilling 
symptom criteria, as described above
1, 24, 25
.
 
Second, these individuals were 
evaluated regarding initial symptoms, course, and additional information 
needed to diagnose or exclude bvFTD (figures 3, 4 and 5). Frontal lobe 
symptoms had to precede severe amnesia or loss of spatial skills for a 
2 (or more) behavioral 
signs in the 
neuropsychiatric 
examination 
2 (or more) behavioral 
signs in the 
neuropsychiatric 
examination 
2 (or more) affective 
signs in the 
neuropsychiatric 
examination 
3 (or more) behavioral 
symptoms in the key 
informant interview 
3 (or more) behavioral 
symptoms in the key 
informant interview 
3 (or more) affective 
symptoms in the key 
informant interview 
Frontal lobe syndrome  
Exclusion criteria: 
# Vascular dementia  
# Early memory loss  
# Early apraxia  
# Early spatial or temporal disorientation                                  
# Chronic alcoholism  
# Schizophrenia 
bvFrontotemporal dementia 
+ + + 
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diagnosis of bvFTD. Likewise, the course of the symptom clusters had to be 
compatible with bvFTD with insidious onset and a progressive, non-episodic 
course. The final diagnosis was reached by consensus between two of the 
authors of paper II (TBG, MSj.).  
The data were collected blindly to any diagnostic aspects, and bvFTD 
diagnoses were set blindly to other dementia diagnoses. 
 
Diagnosis of non-FTD dementia 
Non-FTD dementia was diagnosed according to the Diagnostic and Statistical 
Manual of Mental Disorders, Third edition, revised (DSM-III-R) 
123
. The data 
were collected blindly to any diagnostic aspects, and bvFTD diagnoses were 
set blindly to other dementia diagnoses. 
 
Dementia etiology 
In papers I and IV, individuals with dementia as defined by DSM-III-R were 
classified further into etiological subgroups: Alzheimer's disease (AD) 
according to the criteria of the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer's Disease and 
Related Disorders Association (NINCDS-ADRDA) 
128
, and vascular 
dementia (VAD) as proposed by Erkinjuntti 
129
 (paper I) and the National 
Institute of Neurological Disorders and Stroke and l’Association 
Internationale pour la Recherce et l’Enseignement en Neurosciences 
(NINDS-AIREN) criteria 
130 
(paper IV). 
 
Methods in paper III 
Definitions of potential risk factors 
Medical and psychiatric diagnoses were derived from self-reports, 
neuropsychiatric examinations, key informant interviews and data from the 
Swedish Hospital Discharge Register. Since 1978, everybody admitted to a 
Swedish hospital are registered in a hospital-discharge system with diagnoses 
registered according to the International Statistical Classification of Diseases 
and Related Health Problems (ICD-8, ICD-9 or ICD-10) 
123-125
.  
Blood pressure was measured in the right arm in the seated position after 5 
minutes’ rest with a mercury manometer. Systolic and diastolic blood 
pressures were registered to the nearest 5 mm Hg. Further tests included 
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electrocardiography and an extensive biochemical evaluation. Apolipoprotein 
E isoforms were determined in a subgroup (n=191), using isoelectric 
focusing and Western blotting
131
.  
 
Stroke and/or TIA was only diagnosed among individuals with a definite 
history of acute focal symptoms (e.g. paresis or aphasia) according to self-
reports or key informants, or who received a diagnosis of stroke or TIA in the 
hospital discharge register. All records were examined by neuropsychiatrists, 
who made the final diagnoses
132
. 
Ischemic heart disease: Angina pectoris was diagnosed according to the Rose 
criteria 
133
, and myocardial infarction by history and ECG-evidence of 
ischemia, i.e. complete left bundle branch block or major Q-waves; 
pronounced ST-depression and/or negative T-waves according to the 
Minnesota code 
134
. Angina pectoris and myocardial infarction were also 
diagnosed if a diagnosis was found in the hospital discharge register. 
Concurrent hypertension was defined as a systolic blood pressure > 140 mm 
Hg and/or a diastolic blood pressure > 90 mm Hg at examination, or use of 
antihypertensive treatment at examination. 
Previous hypertension was defined as having been given the diagnosis by a 
doctor or having had previous, but not current, antihypertensive treatment, or 
if a diagnosis was found in the hospital discharge register. 
Diabetes mellitus was diagnosed if the participant had been given the 
diagnosis by a doctor (self-report), if on anti-diabetic treatment (diet and/or 
medication), or if the diagnosis was found in the hospital discharge register. 
Head trauma: Information was obtained from key informants and from the 
hospital discharge register on any type of head trauma. 
Alcohol abuse was defined as alcohol misuse coupled with any type of 
adverse consequences (social, medical and/or psychiatric) as reported from 
key informants, or if a diagnosis of alcohol dependence and/or alcohol-
related medical complications (e.g. alcohol related hepatitis or neuropathy) 
were found in the hospital discharge register. 
Epilepsy and/or seizures: Information regarding any form of seizures was 
obtained from key informants or the hospital discharge register. 
Smoking: Information was obtained from both self-reports and key 
informants and participants were categorized as non-smokers, current 
smokers or former smokers (who ceased smoking >1 year before 
examination).   
Thyroid disease and chronic obstructive pulmonary disease (COPD) were 
defined if the participant had been given the diagnoses by a doctor according 
to self-report (chronic bronchitis), or if the diagnoses were found in the 
hospital discharge register.  
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Family history of dementia: Information on first-degree relatives was 
obtained from both self-reports and key informants. First-degree relatives 
were defined as parents, siblings and offspring of participants. 
Level of education was defined as compulsory education (i.e. 6-7 years) 
versus at least one year of post-compulsory education.   
Neuroinfectious diseases and herpes zoster: Information was obtained from 
the Swedish hospital discharge register.  
Previous depression: Information was obtained from self-reports and key 
informants. 
Concurrent major depression and anxiety disorders (generalized anxiety 
disorder, obsessive-compulsive disorder and phobias) were diagnosed 
according to the Diagnostic and Statistical Manual of Mental Disorders, 
Third edition, revised (DSM-III-R) 
123
. Minor depression was diagnosed 
according to DSM-IV research criteria 
135
. Any depression incorporated both 
minor and major depression.     
 
 
Statistical methods 
Differences in proportions were determined with Pearson’s chi-square (χ2) or, if 
appropriate, Fisher’s Exact Test. Differences in means were assessed with a t-test. 
All p-values were two-tailed and p-values <0.05 were considered statistically 
significant. Cohen's un-weighted kappa was used to assess agreement between 
different criteria. 
Statistical methods specific to paper III 
For each individual with bvFTD, we identified at random 10-14 controls 
without any dementia, matched by age and sex, from the same population-
based sample. We also identified at random 3-4 controls, matched by age and 
sex, among the individuals with global dementia as defined by DSM-III-R. 
Controls had to be free from frontal lobe symptoms as defined by the 
FTDC
25
.  
Possible risk factors included major medical and psychiatric disorders, family 
history of dementia, head trauma and exposure to smoking and alcohol, social 
factors and the presence of white matter lesions on CT (table 13). Conditional 
logistic regression was used to calculate odds ratios and 95% confidence 
intervals (CI). 
 
Thorsteinn B. Gislason 
27 
 
Statistical methods specific to paper IV 
Two comparison groups were selected from the same population as the 
bvFTD cases; one comprised individuals with dementia as defined by DSM-
III-R (but without FTD) and the other comprised individuals without any 
dementia. These comparison groups were larger than the control groups in 
paper III in order to increase power to detect differences in mortality between 
bvFTD and non-FTD dementias. 
Individuals with dementia as defined by DSM-III-R were classified further 
into etiological subgroups: Alzheimer's disease (AD) according to the criteria 
of the National Institute of Neurological and Communicative Disorders and 
Stroke and the Alzheimer's Disease and Related Disorders Association 
(NINCDS-ADRDA) 
128
, and vascular dementia (VAD) according to the 
NINDS-AIREN criteria 
130
.   
Individuals who had three or more frontal lobe symptoms but did not fulfill 
all bvFTD criteria as defined by the FTDC (e.g. having an atypical onset or 
course) were excluded from all comparison groups in order to prevent 
inclusion of bvFTD cases that only partially fulfilled FTDC criteria.
25
  
The associations between the different diagnoses and survival (time to death) 
were calculated with the Kaplan-Meier method. The analyses were also 
stratified by age (70-79, 80-89 and 90-95 years) in order to examine age-
related effects on the survival times. Risk times were calculated from date of 
examination to date of death, or until end of March 2013. A log rank test was 
performed to test differences in survival times between the group with 
bvFTD and the groups with other (non-FTD) dementias, AD, VAD and no 
dementia. Risk times were also calculated from date of symptom onset to 
date of death, or until end of March 2013. Key informant interviews were 
used to determine age of symptom onset. For bvFTD, age of onset was 
defined as the age at which the first FTD symptom appeared. For other (non-
FTD) dementias, age of onset was defined as the age at which memory 
impairment or other dementia symptoms first appeared.  
Cox regression analyses were performed to estimate hazard ratios (HR) for 
death associated with a diagnosis of bvFTD compared to a diagnosis of other 
(non-FTD) dementias, AD, VAD and no dementia. Cox regression analyses 
were performed using time from examination to death (or the end of March 
2013), and also using time from symptom onset to death (or the end of March 
2013). First, the HRs were adjusted for gender and baseline age, and second 
for gender, baseline age and MMSE (as a measure of cognitive function when 
comparing bvFTD and non-FTD dementia). Third, in addition to baseline 
age, the risk of death among the oldest old may also be expected to increase 
during follow-up. Therefore, in order to control for this increasing risk of 
death during follow-up, we adjusted for the age updated in risk time in a third 
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Cox regression analysis (also adjusting for baseline age and gender). Fourth, 
we performed a Cox regression analysis adjusting for gender, baseline age 
and birth cohort, as survival increased in later-born birth cohorts. Fifth, a Cox 
regression analysis was adjusted for stroke/TIA, comparing bvFTD with non-
FTD dementia and no dementia. 
Computerized tomography 
A systematic subsample of 1900 individuals was invited to undergo CT-
scanning of the head, and 1074 accepted (244 men, 830 women). Of these, 
161 had global dementia as diagnosed by DSM-III-R (41 men, 120 women), 
and 913 were without dementia (203 men, 710 women).  
All CT-scans were performed without contrast enhancement and with 10 mm 
continuous slices. The CT-scans were evaluated either by radiologists or a 
neurologist experienced in rating CT-scans. The evaluations were done 
blindly to the results of the neuropsychiatric examination. Location of 
cortical atrophy was categorized as frontal, temporal, parietal or occipital, 
according to the anatomical subdivision
136
. A scale with three grades (absent 
vs. mild vs. moderate or severe) was used to estimate cortical atrophy 
according to the extent of sulcal widening
137
. Inter-rater agreement for the 
assessment of atrophy was “fair” for frontal lobe atrophy (kappa = 0.34) and 
“moderate” for temporal lobe atrophy (kappa =0.43)137. The intra-rater kappa 
values for the assessment of atrophy were “moderate” for frontal lobe atrophy 
(kappa = 0.53) and “good” for temporal lobe atrophy (kappa =0.61) 138, 139. 
White matter lesions (WMLs) were defined as periventricular or subcortical 
areas of decreased attenuation when compared to normal white matter. The 
changes were always diffusely distributed within the white matter. Decreased 
attenuation was subjectively rated on a scale with three grades (no, mild, 
moderate or severe) in relation to the attenuation of normal white matter.
140
 
Inter-rater agreement for the CT assessment regarding the occurrence and 
severity of WMLs was 84% (kappa = 0.75)
140
. 
 
Ethical considerations 
The Ethics Committee for Medical Research at Gothenburg University 
approved all studies. Informed consent was obtained from the participants, 
their nearest relatives, or both.  
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RESULTS 
 
Prevalence of bvFTD among 85-year-olds 
 
The selection of cases for bvFTD in paper I is shown in figure 3. The 
prevalence of bvFTD was 3.1% (n=14; table 7). Of those with bvFTD, 64% 
(n=9) did not fulfill criteria for dementia according to DSM-III-R, and five 
were classified as AD.  
 
Prevalence of FLS among 85-year-olds 
 
The selection procedure for FLS is shown in figure 2. The prevalence of FLS 
was 19% (n=86), with no difference between men and women (table 7). Of 
those with FLS, 75 (87%) were diagnosed with other types of dementia 
according to the DSM-III-R criteria, see table 8. Dementia according to the 
DSM-III-R was diagnosed in 145 (32.2%) individuals, thus 52% (n=75) of 
the demented fulfilled criteria for FLS, compared to 3.6% (n=11) among the 
non-demented.  
Among the eleven individuals who fulfilled criteria for FLS, but not for 
dementia according to DSM-III-R, nine were classified as bvFTD, one had 
early onset of apraxia, and one had a stroke at age 81 with a change in 
personal conduct and aphasia. These two latter cases were therefore not 
diagnosed as bvFTD.  
 
 
Table 7.  The prevalence of frontal lobe syndrome (FLS) and behavioral 
variant frontotemporal dementia (bvFTD) in 85-year-olds. 
 Men Women Total 
 (N=131) (N=320) (N=451) 
 % (n) % (n) % (n) 
FLS 18.9 (25) 19.0 (61) 19.1 (86) 
bvFTD           4.5 (6)            2.5 (8)          3.1 (14) 
 
Gislason et al. J Neurol Neurosurg Psych 2003;74:867-71 
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Frontal atrophy among 85-year-olds 
CT-scan was performed in 238 individuals, including 53 cases of FLS and 6 
cases of bvFTD.  
Among those with FLS 92.5% (N=49) had moderate-severe frontal atrophy, 
as compared to 48.6% (n=90) of those without FLS. All 6 cases with bvFTD 
had moderate-severe frontal atrophy. 
Among those with moderate-severe frontal atrophy (N=139), 49 (35.3%) had 
FLS. Only four (2.9%) among those without moderate-severe frontal atrophy 
had FLS. 
 
 
 
Table 8.  Individuals with frontal lobe syndrome (FLS) among 85-year-olds 
with and without dementia according to DSM-III-R. 
                                                            FLS cases 
   N % 
Dementia      (N=145) 75 51.7 
Types of dementia:   
      AD    (N=63)  32 50.7 
     VAD (N=69)   34 49.3 
      Other (N=13)  9 69.2 
No dementia      (N=306) 11 3.6 
 
Gislason et al. J Neurol Neurosurg Psych 2003;74:867-71 
 
 
Prevalence of bvFTD among 70-95-year-olds 
 
Characteristics of merged sample in paper II are given in table 8. The 
prevalence of bvFTD varied between 0.2-0.5% at age 70-79, between 2.5-
3.6% at age 80-89, and between 1.7-2.2% at age 90-95 using the different 
criteria (table 10 and figure 7).  
Agreement between criteria was low to moderate with kappa values ranging 
from 0.20-0.42 (table 11 and figure 8).  
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Table 9. Demographic characteristics of merged sample in paper II. 
 Men 
% (n) 
Women 
% (n) 
All 
% (n) 
p-value for difference 
between men and 
women 
Age (years)     
 
70-79 
 
16.4 (175) 
 
83.6 (893) 
 
100 (1068) 
 
<0.001 
80-89 22.6 (195) 77.4 (666) 100 (861) <0.001 
90-95 25.0 (133) 75.0 (400) 100 (533) <0.001 
     
Marital status     
Never married 4.4 (22) 9.7 (190) 8.6 (212) <0.001 
Married 55.7 (280) 16.4 (322) 24.5 (602) <0.001 
Divorced 6.4 (32) 15.1 (296) 13.3 (328) <0.001 
Widowed 23.8 (120) 48.4 (947) 43.3 (1067) <0.001 
N/A 9.7 (49) 10.4 (204) 10.3 (253) 0.658 
     
Dementia at 
ages* 
    
70-79 2.3 (5) 5.0 (45) 4.7 (50) 0.211 
80-89 27.7 (54) 34.8 (232) 33.2 (286) 0.063 
90-95 37.6 (50) 54.0 (216) 49.9 (266) 0.001 
Level of 
education** 
 
23.6 (119) 
 
13.2 (258) 
 
15.3 (377) 
 
<0.001 
 
Gislason et al. Alzheimers Dement. 2015;11:425-33 
 
Pearson's chi-square (χ2) or, if appropriate, Fisher’s Exact Test, were used to test differences in 
proportions. 
* Dementia as diagnosed by DSM-III-R. 
** Proportion of individuals with at least one year of post-compulsory education. 
 
 
 
Only 7 out of 88 bvFTD cases diagnosed with at least one set of criteria were 
captured by every set of criteria, and 65 were diagnosed according to only 
one criteria set. Among bvFTD cases, 79% of those diagnosed by FTDC, 
92% of those diagnosed by FTLD-CC, and 53% of those diagnosed by 
LMRC had dementia according to DSM-III-R (p<0.05 FTDC vs. LMRC; 
p>0.05 FTDC vs. FTLD-CC; p<0.05, FTLD-CC vs. LMRC).  
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Table 10. The prevalence of the behavioral variant of frontotemporal 
dementia (bvFTD) between age 70 and 95 years using three sets of criteria. 
 
                                                                        Gislason et al. Alzheimers Dement. 2015;11:425-33 
 
FTDC: Criteria of the International Behavioral Variant FTD Criteria Consortium.  
FTLD-CC: Frontotemporal Lobar Degeneration Consensus Criteria.  
LMRC: Lund-Manchester Research Criteria.  
 
 
 
 
Dementia severity as measured by MMSE was not significantly associated 
with bvFTD as diagnosed by any diagnostic criteria (FTDC: p=0.791; FTLD-
CC: p=0.066; LMRC: p=0.353). Furthermore, dementia severity as measured 
by MMSE was not significantly associated with frontal and/or temporal lobe 
atrophy (FTDC: p=0.301; FTLD-CC: p=0.101; LMRC: p=0.333). 
 
 
 
 
 
 
 
 
 
 FTDC 
%(n) 
FTLD-CC 
% (n) 
LMRC 
% (n) 
Age 
70-79  (n=1068) 0.5 (5) 0.3 (3) 0.2 (2) 
95% CI (0.2-1.9) (0.1-0.8) (0.1-0.7) 
80-89  (n=861) 3.6 (31) 2.5 (22) 2.7 (23) 
95% CI (2.5-5.1) (1.7-3.8) (1.8-4.0) 
90-95  (n=533) 2.2 (12) 1.7 (9) 2.1 (11) 
95%  CI (1.3-3.9) (0.9-3.2) (1.1-3.6) 
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Figure 7. The prevalence of the behavioral variant of 
frontotemporal dementia (bvFTD) between age 70 and 95 years 
using three sets of criteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 11. Agreement between LMRC, FTLD-CC and FTDC criteria for 
behavioral variant frontotemporal dementia (bvFTD). 
 FTDC 
n (%) 
FTLD-CC 
n (%) 
LMRC 
n (%) 
FTDC (n=48) X 13 (27.1) 17 (35.4) 
Kappa  0.30 0.42 
FTLD-CC (n=34) 13 (38.2) X 7 (20.6) 
Kappa 0.30  0.20 
LMRC (n=36) 17 (47.2) 7 (19.4) X 
Kappa 0.42 0.20  
                                                                              Gislason et al. Alzheimers Dement. 2015;11:425-33 
 
Cohen's un-weighted kappa was used to assess agreement between different criteria. 
FTDC: Criteria of the International Behavioral Variant FTD Criteria Consortium.  
FTLD-CC: Frontotemporal Lobar Degeneration Consensus Criteria.  
LMRC: Lund-Manchester Research Criteria.  
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Figure 8. The agreement between criteria for behavior variant 
frontotemporal dementia. 
 
Gislason et al. Alzheimers Dement. 2015;11:425-33 
 
Cohen's un-weighted kappa was used to assess agreement between different criteria. 
FTDC: Criteria of the International Behavioral Variant FTD Criteria Consortium.  
FTLD-CC: Frontotemporal Lobar Degeneration Consensus Criteria.  
LMRC: Lund-Manchester Research Criteria.  
 
 
Frontal/temporal atrophy 
CT-scan was performed in 1074 individuals. Among these, 1.4% (n=15) had 
bvFTD according to FTDC, 1.0% (n=11) according to FTLD-CC and 0.7% 
(n=8) according to LMRC. 
Furthermore, 89.4 % (n=960) of the participants in the CT examination did 
not have frontal lobe symptoms as defined by any of the three criteria sets (no 
frontal lobe symptoms; non-FLS). In this group the prevalence of moderate-
severe frontal atrophy was 8.9% (n=85) and out of these 11.8% (n=10) had 
global dementia as diagnosed by DSM-III-R. Furthermore, in the non-FLS 
group, the prevalence of moderate-severe temporal atrophy was 8.1% (n=78) 
and 19.2% (n=15) of these had global dementia. In the non-FLS group the 
prevalence of moderate-severe frontal and/or temporal atrophy was 4.4% 
(n=42) with 42.8% (n=18) having global dementia. 
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The association between frontal and/or temporal lobe atrophy and the 
bvFTD-diagnoses is shown in table 12. Among 15 cases with bvFTD, 14 
(93.3%) had moderate-severe frontal and/or temporal atrophy compared to 
12.6% in the non-FLS group (p<0.001). Among 11 persons with bvFTD 
according to FTLD-CC, 7 (63.6%) had moderate-severe frontal and/or 
temporal atrophy (p<0.001 compared to non-FLS). All 8 persons with bvFTD 
according to LMRC had moderate-severe frontal and/or temporal atrophy 
(p<0.001 compared to non-FLS). 
 
Table 12. Frontal and/or temporal lobe atrophy on CT scan of the brain in 
relation to a diagnosis of behavior variant frontotemporal dementia (bvFTD) 
according to different FTD criteria. 
  
Frontal and temporal lobe atrophy† on CT scan of the brain 
 
 
Frontal lobe 
atrophy 
 
Temporal lobe 
atrophy 
 
 
Both frontal and 
temporal lobe 
atrophy 
 
Frontal and/or 
temporal lobe 
atrophy 
bvFTD 
criteria 
% (n) % (n) % (n) % (n) 
FTDC 
(n=15) 
80.0 (12)* 73.3 (11)* 60.0 (9)* 93.3 (14)* 
FTLD-CC 
(n=11) 
45.4 (5)* 54.5 (6)* 36.4 (4)** 63.6 (7)* 
LMRC 
(n=8) 
75.0 (6)* 75.0 (6)* 50.0 (4)* 100 (8)* 
     
Non-FLS 
(n=960) 
8.9 (85) 8.1 (78) 4.4 (42) 12.6 (121) 
 
† “Atrophy” refers to moderate or severe lobar atrophy. 
 
FTDC: Criteria of the International Behavioral Variant FTD Criteria Consortium. 
FTLD-CC: Frontotemporal Lobar Degeneration Consensus Criteria. 
LMRC: Lund-Manchester Research Criteria. 
Non-FLS: Participants in the CT examination who did not have frontal lobe symptoms as defined by any 
of the three criteria sets (FTDC, FTLD-CC or LMRC). 
 
*p<0.001 for difference between bvFTD diagnosis and non-FLS (Fisher’s exact test, two-tailed).   
**p=0.001 for difference between bvFTD diagnosis and non-FLS (Fisher’s exact test, two-tailed). 
 
Gislason et al. Alzheimers Dement. 2015;11:425-33 
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Table 13. Characteristics of individuals with a diagnosis of behavior variant 
frontotemporal dementia (bvFTD) and controls (paper III). 
 bvFTD 
 
Controls 
without 
dementia 
p-value 
 
Controls with non-
FTD dementia† 
p-value 
 
 (n=48) (n=673)  (n=168)  
Mean age (years)  86.6 86.6 0.943 86.7 0.876 
Gender  
[% women (n)] 
 81.2 (39/48) 79.6 (536/673) 0.791 81.6 (137/168) 0.962 
Residence in nursing home  
[% (n)] 
47.9 (23/48) 4.0 (27/673) <0.001 23.2 (39/168) <0.001 
MMSE score  
(mean +SD) 
16.5 (+8.8) 26.9 (+2.9) <0.001 17.7 (+6.9) 0.430 
MADRS (mean+SD) 9.73 (+9.02) 6.72 (+6.38) 0.029 8.13 (+7.33) 0.343 
Depressive disorders 
[% (n)]   
     
  Any            33.3 (16/48) 24.5 (165/673) 0.006 29.8 (50/168) 0.639 
Major 18.7 (9/48) 17.5 (118/673) 0.040 11.3 (19/168) 0.176 
Minor 14.6 (7/48) 9.1 (61/673) 0.647 18.4 (31/168) 0.532 
Anxiety disorders 
[% (n)] 
25.0 (12/48) 20.4 (137/673) 0.442 13.7 (23/168) 0.061 
GAD 18.7 (9/48) 11.0 (74/673)  0.104 10.7 (18/168) 0.138 
OCD 2.1 (1/48) 2.5 (17/673)  0.660 0.6 (1/168) 0.396 
Phobias 4.2 (2/48) 11.9 (80/673)  0.103 3.6 (6/168) 0.563 
Auditory hallucinations*  
[% (n)] 
8.3 (3/36) 0.5 (3/564) 0.003 2.5 (3/122) 0.132 
Visual hallucinations* 
[% (n)] 
2.8 (1/36) 1.1 (6/564) 0.353   2.5 (3/122) 0.648 
Impaired hearing  
[% (n)] 
32.6 (15/46) 17.0 (109/641) 0.024 32.7 (55/168) 0.767 
Visual impairment [%(n)] 7.5 (3/40) 9.0 (56/622) 0.514 15.5 (26/168) 0.191 
Cortical atrophy on CT  
[% (n)] 
     
Frontal lobe  80.0 (12/15) 15.1 (35/231) <0.001 29.8 (11/37) 0.002 
Temporal lobe  73.3 (11/15) 14.3 (33/231) <0.001 43.2 (16 /37) 0.068 
 
Pearson's chi-square (χ2) or, if appropriate, Fisher’s Exact Test, were used to test differences in 
proportions. Differences in means were assessed with a t-test.  
 
*According to self-reports. 
† Other (non-FTD) dementia as defined by DSM-III-R. 
 
Risk factors (Paper III) 
Characteristics of cases and controls are given in table 13, including 
concurrent psychiatric diagnoses, psychotic symptoms, and visual and/or 
hearing impairment. Delusions were rare among the FTD cases (2.8%; 
n=1/36), and paranoid ideation and non-visual, non-auditory hallucinations 
were not present among the bvFTD cases.  
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Table 14 shows unadjusted comparisons between bvFTD and the two control 
groups, with and without dementia.   
Comparisons between bvFTD and controls without dementia: Stroke and/or 
TIA, hypothyroidism, head trauma, alcohol abuse, severe white matter 
lesions (WMLs) on CT of the brain and being divorced were associated with 
increased odds of bvFTD. Light-moderate alcohol use and being married 
were associated with decreased odds of bvFTD. There was a trend for history 
of herpes zoster (p=0.097) and being widowed (p=0.051) to be associated 
with bvFTD. 
Comparisons between bvFTD and controls with dementia: Alcohol abuse and 
being divorced were associated with increased odds of bvFTD. Being married 
was associated with decreased odds of bvFTD. Hypothyroidism tended to be 
associated with increased odds of bvFTD (p=0.070). 
Family history of dementia among first-degree relatives, ApoE ε4 status, 
diabetes mellitus, ischemic heart disease and history of previous depression 
were not related to bvFTD. No participant was diagnosed with meningitis or 
encephalitis. 
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Table 14. History of medical problems and environmental exposures among 
behavior variant frontotemporal dementia (bvFTD) cases and controls 
(paper III).  
 bvFTD 
% (n/N) 
Controls without 
dementia 
% (n/N) 
OR  
(95% CI) 
Controls with non-
FTD dementia† 
% (n/N) 
OR 
(95% CI) 
Stroke/TIA a 35.4 (17/48) 18.7 (126/673) 2.11 (1.09-4.09)* 42.9 (72/168) 0.66 (0.31-1.42) 
Ischemic heart disease b 35.4 (17/48) 42.3 (285/673) 0.69 (0.36-1.33) 30.9 (52/168) 1.13 (0.52-2.45) 
Hypertension      
Concurrent 68.7 (33/48) 75.3 (510/673) 0.52 (0.21 - 1.26) 55.4 (93/168) 1.58 (0.64-3.95) 
Previous 29.2 (14/48) 31.2 (210/673) 0.91 (0.48- 1.73) 20.2 (34/168) 1.62 (0.78-3.36) 
Diabetes mellitus 10.4 (5/48) 9.5 (64/673) 1.04 (0.40-2.70) 8.9 (15/168) 1.19 (0.41-3.45) 
Hypothyroidism 16.7 (8/48) 8.3  (56/673) 2.59 (1.10-6.11)* 5.4 (9/168) 2.72 (0.92-8.01) 
Seizures or epilepsy 6.3 (3/48) 5.0 (34/673) 1.20 (0.35-4.11) 10.7 (18/168) 0.54 (0.14-2.08) 
COPD c 2.1 (1/48) 2.2 (15/673) 0.93 (0.12-7.22) 3.0 (5/168) 0.69 (0.08-6.08) 
Herpes zoster 6.2 (3/48) 1.8 (12/673) 2.94 (0.82-10.55) 2.4 (4/168) 3.14 (0.68-14.45) 
Prior depression d 33.3 (16/48) 24.5 (165/673) 1.54 (0.83-2.87) 34.5 (58/168) 0.95 (0.48-1.87) 
Head trauma 18.7 (9/48) 8.0 (54/673) 2.92 (1.28-6.65)* 19.0 (32/168) 0.98 (0.43-2.23) 
Alcohol abuse 18.7 (9/48) 1.6 (11/673) 14.85 (5.64-39.07)*** 4.2 (7/168) 3.52(1.12-11.09)* 
Light-moderate alcohol use 58.2 (25/43) 72.5 (381/525) 0.52 (0.28-0.99)* 66.1 (111/168) 0.71 (0.36-1.41) 
Smoking      
Non-smoker 65.9 (29/44) 52.7 (350/664) 1.73 (0.91-3.29) 57.0 (90/158) 1.46 (0.73-2.94) 
Former smoker 29.6 (13/44) 33.4 (222/664) 0.83 (0.43-1.63) 35.4 (56/158) 0.76 (0.37-1.58) 
Current smoker 4.5  (2/44) 13.9 (92/664) 0.30 (0.07-1.24) 7.6 (12/158) 0.58 (0.12-2.69) 
Level of education e 19.0 (8/42) 32.2 (187/581) 0.51 (0.13-2.03) 28.8 (32/111) 0.58 (0.24-1.39) 
Marital status      
Never married 18.7 (9/48) 11.6 (78/673) 1.76 (0.82-3.77) 14.1 (23/168) 1.40 (0.60-3.28) 
Married 14.6 (7/48) 47.4 (319/673) 0.19 (0.08-0.43)*** 33.7 (55/168) 0.33 (0.14-0.80)** 
Divorced 18.7 (9/48) 7.0 (47/673) 3.19 (1.37-7.40)** 3.1 (5/168) 8.06  
(2.35-27.59)** 
Widowed 48.0 (23/48) 34.0 (229/673) 1.78 (0.99-3.21) 51.5 (84/168) 0.86 (0.45-1.65) 
Family history of dementia 
after age 65 
14.6 (7/48) 16.9 (114/673) 0.84 (80.37-1.91) 21.4 (36/168) 0.63 (0.26-1.51) 
Family history of dementia 
before age 65 
2.1 (1/48) 1.8 (12/673) 1.17 (0.15-9.21) 1.2 (2/168) 1.77 (0.16-19.90) 
Any APOE ε4 allele genotype 33.3 (3/9) 34.4 (53/154) 0.95 (0.23-3.96) 53.6 (15/28) 0.43 (0.09-2.09) 
Severe WMLs f 33.3 (5/15) 6.1 (14/231) 7.75 (2.33-25.78)** 35.1 (13/37) 0.92 (0.26-3.28) 
 
Conditional logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI). 
 
*p<0.05 for OR. 
 **p<0.01 for OR.  
***p<0.001 for OR. 
 
†Other (non-FTD) dementia as defined by DSM-III-R. 
a) Stroke and/or transient ischemic attack (TIA).  
b) Angina pectoris and/or myocardial infarction.  
c) COPD: Chronic obstructive pulmonary disease or chronic bronchitis. 
d) Prior depression over the life course as reported by key informant. 
e) Proportion of individuals who have at least one year of education after finishing compulsory education. 
f) WMLs: White matter lesions. 
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Mortality (Paper IV) 
The characteristics of the study population are shown in table 15. During 
follow-up 904 individuals died (61.8% of cases and comparison groups 
combined). Mean follow-up time was 7.90 years (95% CI: 7.68-8.12). 
Stroke/TIA was more common among individuals with bvFTD than among 
individuals with no dementia, but did not differ compared to non-FTD 
dementia. There were no other differences between individuals with bvFTD 
and individuals with other (non-FTD) dementias or no dementia regarding 
history of ischemic heart disease, diabetes mellitus or COPD.  
 
Participants had a lower risk of death than non-participants (HR=0.83; 95% 
CI: 0.75-0.90; p<0.001). There was a lower risk of death among 70-79-year-
old participants compared to non-participants (p<0.001), but there was no 
significant difference in risk of death between participants and non-
participants in the age groups 80-89-year-olds (p=0.181) and 90-95-year-olds 
(p=0.314). 
 
Table 16 shows that HR for death was higher among those with bvFTD 
compared to those with other (non-FTD) dementias, AD, and no dementia, 
both when examining risk time from examination and risk time from 
symptom onset to death (or end of March 2013). In all adjusted analyses, 
bvFTD was associated with a higher risk of death compared to other (non-
FTD) dementias, AD and no dementia. Controlling for cognitive function 
(MMSE) and birth cohort did not influence the results. Controlling for 
stroke/TIA did not influence the results when comparing bvFTD with non-
FTD dementia (HR=1.58; 95% CI: 1.11-2.27; p=0.012), or with no dementia, 
although in the latter instance, the HR was lower than in other adjusted 
analyses (HR=2.98; 95% CI: 208-4.28; p<0.001). Also, when examining time 
from symptom onset to death, bvFTD was associated with a higher risk of 
death compared to VAD (controlling for age at symptom onset and gender) 
and tended to be associated with a higher risk of death compared to VAD 
when controlling for cognitive function (p=0.062) and birth cohort (p=0.092). 
Furthermore, when examining time from examination to death, a diagnosis of 
bvFTD tended to be associated with a higher risk of death compared to VAD 
(p=0.089). 
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Table 15. Characteristics and medical co-morbidities of individuals with a 
diagnosis of behavior variant frontotemporal dementia (bvFTD) compared 
with individuals without dementia and individuals with other (non-FTD) 
dementia, Alzheimer’s disease and vascular dementia (paper IV). 
 bvFTD 
(n=48) 
Non-FTD 
dementia a 
(n=265) 
Alzheimer’s 
disease b 
(n=124) 
Vascular 
dementia c 
(n=88) 
 
Without 
dementia 
(n=1149) 
Gender 
[% women (n)] 
 81.2 (39) 81.5 (216)  85.5 (106) 82.9 (73) 78.8 (905) 
      
Mean age  
[years (95% CI)]              
     
All 
86.6 
(84.9-88.2) 
88.2  
(87.4-88.9) 
87.6  
(86.3-88.9) 
87.3 
(85.8-88.8) 
79.1***  
(78.7-79.5) 
Women 
86.5 
(84.8-88.3) 
88.1 
(87.3-88.9) 
87.6  
(86.2-89.0) 
87.2 
(85.6-88.8) 
78.7*** 
(78.3-79.2) 
Men 
86.8 
(81.4-92.2) 
88.4 
(86.6-90.2) 
87.7  
(83.8-91.6) 
87.8 
(83.2-92.4) 
80.4* 
(79.4-81.3) 
      
Proportion living in 
nursing home [% (n)] 
47.9 (23) 24.2 (64)*** 28.2 (35)* 27.3 (24)* 4.0 (46)*** 
      
MMSE score, mean  
(95% CI) 
16.5 
(14.0-19.1) 
19.1 
(18.3-19.9) 
18.7 
(17.4-20.0) 
18.5 
(17.1-19.9) 
27.6*** 
(27.5-27.7) 
      
Ischemic heart disease e 35.4 (17) 27.5 (73) 23.4 (29) 37.5 (33)  30.1 (346) 
Stroke/TIA d 31.2 (15) 40.7 (108) 17.7 (22)† 100 (88)  16.9 (194)* 
Diabetes mellitus f 10.4 (5) 8.7 (23) 4.8 (6) 10.2 (9)  9.5 (109) 
COPDg 2.1 (1)  3.0 (8) 1.6 (2) 4.5 (4) 2.3 (26) 
 
Differences in means between bvFTD and comparison groups were tested with a t-test (two-tailed) and 
differences in proportions with Pearson's chi-square, two-tailed. 
*p<0.05 compared to bvFTD. 
 **p<0.01 compared to bvFTD.  
***p<0.001 compared to bvFTD. 
†0.053 compared to bvFTD. 
 
a) Non-FTD dementia as defined by DSM-III-R. 
b) Alzheimer’s disease as defined by the NINCDS-ADRDA criteria. 
c) Vascular dementia as defined by the NINDS-AIREN criteria. 
d) Stroke and/or transient ischemic attack (TIA). A comparison between bvFTD and VAD was not 
performed, as all individuals with VAD had some type of cerebrovascular episode by definition.  
e) Angina pectoris and/or myocardial infarction. 
f) Diabetes mellitus, any type. 
g) COPD: Chronic obstructive pulmonary disease or chronic bronchitis. 
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Table 16. Hazard ratios (HR) for death associated with a diagnosis of 
behavior variant frontotemporal dementia (bvFTD) compared to a diagnosis 
of non-FTD dementias (DSM-III-R), Alzheimer’s disease, vascular dementia 
and no dementia. Risk time from time of examination (A) and from symptom 
onset (B). 
Risk time HR 
(95% CI) 
HR 
(95% CI) 
HR 
(95% CI) 
HR 
(95% CI) 
A. From 
examination 
Adjusted for age 
at onset, gender 
Adjusted for age 
updated in risk 
time, gender 
Adjusted for age at 
onset, gender, 
MMSE 
Adjusted for age 
at onset, gender, 
birth cohort 
Non-FTD 
dementia a 
ref ref ref ref 
bvFTD 
1.65 
(1.19-2.31)** 
1.63 
(1.17-2.26)** 
1.53 
(1.09-2.14)** 
1.64 
(1.18-2.28)** 
             
Alzheimer’s 
disease b 
ref ref ref ref 
bvFTD    
1.92 
(1.34-2.75)*** 
1.85 
(1.29-2.65)** 
1.59 
(1.09-2.30)* 
1.80 
(1.25-2.57)** 
Vascular 
dementia c  
ref ref ref ref 
bvFTD    
1.38 
(0.95-2.00) 
1.40 
(0.96-2.04) 
1.37 
(0.94-2.00) 
1.37 
(0.94-1.98) 
No dementia ref ref - ref 
bFTD 
3.98 
(2.85-5.55)*** 
3.75 
(2.68-5.25)*** 
- 3.61 
(2.58-5.05)*** 
     
B. From 
symptom onset 
    
Non-FTD 
dementia a 
ref ref ref ref 
bvFTD          1.77 
(1.29-2.43)*** 
1.60 
(1.16-2.22)** 
1.84 
(1.33-2.54)*** 
1.75 
(1.27-2.40)* 
Alzheimer’s 
disease b 
ref ref ref ref 
bvFTD    1.82 
(1.27-2.61)** 
1.75 
(1.23-2.50)** 
1.53 
(1.07-2.19)* 
1.78 
(1.24-2.55)** 
Vascular 
dementia c  
ref ref ref ref 
bvFTD    1.51 
(1.04-2.20)* 
1.40 
(0.97-2.03) 
1.42 
(0.98-2.06) 
1.37 
(0.95-2.00) 
 
Results were obtained with Cox regression analyses, using time from examination (A) or time from 
symptom onset (B) to death or end of March 2013. 
 
*p<0.05 compared to bvFTD. 
 **p<0.01 compared to bvFTD.  
***p<0.001 compared to bvFTD. 
 
a) Non-FTD dementia as defined by DSM-III-R. 
b) Alzheimer’s disease as defined by the NINCDS-ADRDA criteria. 
c) Vascular dementia as defined by the NINDS-AIREN criteria. 
Frontotemporal dementia in late life 
42 
 
Table 17 shows 3-year mortality, 10-year mortality and median survival from 
time of examination to death in relation to bvFTD, other (non-FTD) 
dementias and no dementia, stratified by age group. Between ages 80-89 
years, median survival time was shorter among those diagnosed with bvFTD 
(2.6 years) than among those with other (non-FTD) dementias (4.3 years; log 
rank test: p=0.018) and those with AD (4.5 years; p=0.008). Between ages 
90-95 years, median survival time was shorter among those with bvFTD (1.1 
years) than among those with other (non-FTD) dementias (1.7 years; 
p=0.016) and those with AD (1.9 years; p=0.041). There was no difference in 
survival times between bvFTD and VAD. Furthermore, median survival time 
was shorter among those diagnosed with bvFTD than among those with no 
dementia regardless of age group. Among individuals with bvFTD, there was 
no difference in survival times among men compared to women (median 
survival 2.4 years vs. 2.5 years; p=0.131). Figure 9 shows the cumulative 
proportion surviving from time of examination to death (or end of March 
2013) as determined by the Kaplan-Meier method, in relation to diagnoses of 
bvFTD, AD, VAD and being without dementia. 
Mean age of onset was 83.1 years (95% CI: 81.3-84.8) among the bvFTD 
cases and 83.8 years (95% CI: 82.9-84.8) among those with other (non-FTD) 
dementias (p=0.431). Table 18 shows median survival times from time of 
symptom onset to death in relation to bvFTD and other (non-FTD) dementias 
stratified by age group. Between ages 80-89 years, median survival time was 
shorter among bvFTD cases (7.4 years) than among those with other (non-
FTD) dementias (8.8 years; log rank test: p=0.016). However, between ages 
70-79 years and 90-95 years there were no differences in survival times 
between individuals with bvFTD and other (non-FTD) dementias.  
Table 19 shows that excluding individuals aged 70-79 years did not influence 
the results. 
Causes of death according to death certificates for individuals with a 
diagnosis of bvFTD, other (non-FTD) dementias and no dementia are shown 
in table 20. The most common causes of death in bvFTD were cardiovascular 
disorder, dementia and infectious disease. There were no differences in 
causes of death between individuals with bvFTD and those with other (non-
FTD) dementias, except that dementia was more often a cause of death in 
individuals with bvFTD compared to those with VAD. Dementia was also 
more common as a cause of death in individuals with bvFTD compared to 
individuals with no dementia. Malignant disorders tended to be a less 
frequent cause of death in bvFTD compared to individuals with no dementia. 
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Table 17. Median survival times from time of examination to death, 3-year 
mortality and 10-year mortality for individuals with a diagnosis of behavior 
variant frontotemporal dementia (bvFTD) compared to other (non-FTD) 
dementias, Alzheimer’s disease, vascular dementia or no dementia, stratified 
by age. 
 Median survival times [years (95% CI)] 
Age bvFTD      Other 
 (non-FTD) 
dementias a   
Alzheimer’s 
disease b 
Vascular 
dementia c 
No dementia 
      
All (70-95 years)              2.41  
(2.04-2.78) 
2.78  
(2.30-3.27) 
2.88 
 (2.05-3.71) 
3.09  
(2.34-3.82) 
10.44  
(9.67-11.21)*** 
        Women  2.54  
(2.08-3.00) 
2.89  
(2.48-3.31) 
2.91  
(2.11-3.71) 
3.16  
(2.61-3.72) 
10.91  
(10.27-11.54)*** 
          Men  2.39  
(1.77-3.00) 
1.88  
(1.19-2.58) 
2.03  
(1.60-2.47) 
0.78  
(0.20-2.59) 
7.09  
(6.03-8.14)*** 
      
Age (years)      
70-79   9.02  
(7.82-10.23) 
6.93  
(4.13-9.72) 
8.46  
(7.54-9.37) 
5.60  
(3.47-7.72) 
 15.91  
(15.43-16.40) 
*** 
80-89  2.60  
(1.57-3.62) 
4.33 
 (3.21-5.45)* 
4.53  
(3.65-5.41)** 
3.32  
(2.03-4.60) 
6.43  
(6.01-6.85)*** 
90-95  1.13  
(0.47-1.79) 
1.69  
(1.31-2.07)* 
1.88  
(0.98-2.78)* 
1.51 
 (0.55-2.46) 
3.45  
(3.01-3.89)*** 
      
  3-year mortality [% (n/N)] 
All (70-95 years) 62.5 (30/48)  52.8 (140/265) 51.6 (64/124) 48.9 (43/88) 13.8 
(159/1149)*** 
Age (years)      
70-79  (0/5) 14.8 (4/27) 11.8 (2/17) 15.4 (2/13)  3.1 (20/635) 
80-89        58.1 (18/31) 37.1 (39/105)d 36.7 (22/60)e 40.9 (18/44)  19.5 (68/349)*** 
90-95  100.0 (12/12) 74.4 (99/133)f 72.3 (34/47)g 83.9 (26/31) 43.0 (71/165)*** 
      
 10-year mortality [% (n/N)] 
All (70-95 years)              95.8 (46/48) 93.6 (248/265) 91.9 (114/124) 92.0 (81/88) 49.6 
(570/1149)*** 
Age (years)      
70-79  60.0 (3/5) 66.7 (18/27) 64.7 (11/17) 69.2 (9/13) 21.1 
(134/635)*** 
80-89         100.0 (31/31) 92.4 (97/105) 93.3 (56/60) 93.2 (41/44) 79.1 (276/349)* 
90-95  100.0 (12/12) 100.0 (133/133) 100.0 (47/47) 100.0 (31/31) 97.0 (160/165) 
 
The Kaplan-Meier method was used to determine median survival times from time of examination to death 
or end of March 2013. A log-rank test was used to compare the median survival time of bvFTD with the 
median survival times of non-FTD dementias, AD, VAD and no dementia. 
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Table 17 cont.: 
 
*p<0.05 compared to bvFTD. 
 **p<0.01 compared to bvFTD.  
***p<0.001 compared to bvFTD. 
 
a) Other (non-FTD) dementias as defined by DSM-III-R. 
b) Alzheimer’s disease as defined by the NINCDS-ADRDA criteria. 
c) Vascular dementia as defined by the NINDS-AIREN criteria. 
d) p=0.061 compared to bvFTD. 
e) p=0.074 compared to bvFTD. 
f) p=0.069 compared to bvFTD. 
g) p=0.051 compared to bvFTD. 
 
 
Table 18. Median survival times from time of symptom onset to death for 
individuals with a diagnosis of behavior variant frontotemporal dementia 
(bvFTD) and other (non-FTD) dementias, Alzheimer’s disease and vascular 
dementia, stratified by age. 
 
Median survival times [years (95% CI)] 
 bvFTD      Other  
(non-FTD) 
dementias a   
Alzheimer’s 
disease b 
Vascular  
dementia c 
All (70-95 years)  6.91  
(5.60-8.22) 
7.36  
(6.67-8.05)  
7.51  
(6.43-8.59)  
7.12  
(5.77-8.47)  
Age (years)     
70-79   13.19  
(5.16-21.22) 
11.80  
(4.74-18.86)  
9.10  
(7.83-10.37)  
13.56 
 (6.74-20.39)  
     
80-89  7.39 
 (5.94-8.84) 
8.82  
(7.87-9.76)*  
9.00  
(6.90-11.08)*  
8.34  
(6.78-9.89)  
     
90-95  4.63 
 (3.06-6.19) 
5.55 
 (4.70-6.40)  
4.84 
 (4.39-5.29)  
3.97  
(2.30-5.64)  
 
The Kaplan-Meier method was used to determine median survival times from time of symptom onset to 
death or end of March 2013. A log-rank test was used to compare the median survival time of bvFTD with 
the median survival times of other (non-FTD) dementias, Alzheimer’s disease and vascular dementia. 
 
*p<0.05 compared to bvFTD. 
  
a) Other (non-FTD) dementias as defined by DSM-III-R. 
b) Alzheimer’s disease as defined by the NINCDS-ADRDA criteria. 
c) Vascular dementia as defined by the NINDS-AIREN criteria. 
 
 
Thorsteinn B. Gislason 
45 
 
Table 19. Hazard ratios (HR) for death among individuals aged 80 years and 
older, associated with a diagnosis of behavior variant frontotemporal 
dementia (bvFTD) compared to a diagnosis of other (non-FTD) dementias 
(DSM-III-R), Alzheimer’s disease, vascular dementia and no dementia. Risk 
time from symptom onset. 
 HR 
(95% CI) 
HR 
(95% CI) 
HR 
(95% CI) 
HR 
(95% CI) 
 Adjusted for age at 
onset, gender 
Adjusted for age 
updated in risk 
time, gender 
Adjusted for age at 
onset, gender, 
MMSE 
Adjusted for age 
at onset, gender, 
birth cohort 
Non-FTD 
dementia a 
ref ref ref ref 
bvFTD          1.66 
(1.20-2.31)** 
1.51 
(1.29-2.58)*** 
1.58 
(1.13-2.21)** 
1.66 
(1.20-2.31)** 
     
Alzheimer’
s disease b 
ref ref ref ref 
bvFTD    1.96 
(1.36-2.84)*** 
1.96 
(1.34-2.88)*** 
1.67 
(1.14-2.46)** 
1.95 
(1.34-2.82)*** 
     
Vascular 
dementia c  
ref ref ref ref 
bvFTD    1.43 
(0.98-2.11) 
1.67 
(1.11-2.50)* 
1.41 
(0.96-2.08) 
1.43 
(0.97-2.10) 
     
No 
dementia 
ref ref - ref 
bvFTD           3.62 
(2.67-4.90)*** 
3.39 
(2.37-4.86)*** 
- 3.49 
(2.58-4.73)*** 
 
Results were obtained with Cox regression analyses, using time from examination to death or end of 
March 2013. 
*p<0.05 compared to bvFTD. 
 **p<0.01 compared to bvFTD.  
***p<0.001 compared to bvFTD. 
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Figure 9. Survival rate in relation to behavior variant frontotemporal 
dementia (bvFTD), Alzheimer’s diseasea, vascular dementiab and 
being without dementia. 
 
 
Survival rate was determined by Kaplan-Meier analysis. 
a) Alzheimer’s disease as defined by the NINCDS-ADRDA criteria. 
b) Vascular dementia as defined by the NINDS-AIREN criteria. 
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Table 20. Cause of death according to death certificates for individuals with 
a diagnosis of behavior variant frontotemporal dementia (bvFTD), other 
(non-FTD) dementias and no dementia. Death certificate was obtained from 
The Swedish Health and Welfare Statistical Database for Cause of Death. 
 bvFTD 
(n=48) 
Other  
(non-FTD) 
dementias a 
(n=259) 
Alzheimer’s 
disease b 
(n=118) 
Vascular 
dementia c 
(n=88) 
No 
dementia 
(n=880) 
 % (n) % (n) % (n) % (n) % (n) 
Cardiovascular 
disorder d 
35.5 (17) 40.1 (104) 37.4 (44) 43.1 (38) 39.2 (345) 
CVD e 8.3 (4) 14.3 (37)  14.4 (17) 15.9 (14) 11.6 (102) 
Dementia 25.0 (12) 16.6  (43)  20.3 (24) 10.2 (9)* 9.8 (86)*** 
Infectious 
disease 
14.6 (7)  11.6 (30) 12.7 (15) 8.0 (7) 7.9 (70) 
Malignancy f 8.3 (4)  8.1 (21)  5.9 (7) 8.0 (7) 19.0 (167)† 
Other cause 8.3 (4) 9.3 (24)  9.3 (11) 14.8 (13) 12.5 (110) 
 
*p<0.05 compared to bvFTD (Pearson's chi-square, two-tailed).  
***p<0.001 compared to bvFTD.   
†p=0.083 compared to bvFTD. 
 
a) Other (non-FTD) dementias as defined by DSM-III-R. 
b) Alzheimer’s disease as defined by the NINCDS-ADRDA criteria. 
c) Vascular dementia as defined by the NINDS-AIREN criteria. 
d) Includes any diagnosis of ischemic heart disease, heart failure, cardiomyopathy and arrhythmia as cause 
of death according to death certificate.  
e) Includes any diagnosis of a cerebrovascular disorder (CVD) as cause of death according to death 
certificate. 
f) Includes any diagnosis of a malignant disorder, including hematological malignancies, as cause of death 
according to death certificate. 
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DISCUSSION 
 
Prevalence of bvFTD 
We examined the prevalence of possible bvFTD in an elderly general 
population, using the LMRC in paper I and three different FTD criteria in 
paper II. Paper I can be thought of as a pilot study for the later investigation, 
and yielded the results that bvFTD (as detected by the LMRC) was more 
common among 85-year-olds than previously supposed. Paper II describes 
the prevalence of bvFTD among 70-95-year-olds according to three different 
FTD criteria, and irrespective of criteria, bvFTD was more common among 
older adults than expected. Furthermore, we found a higher prevalence at age 
81-95 than at age 70-79 years.  
 
It is believed that FTD occurs mainly among individuals aged 45–65 years79, 
80
, and most prevalence studies have been performed in this age group
4
. Most 
studies in populations above age 65 years have reported lower rates (0-
0.6%)
74-77
 than this study. Prevalence estimates for the elderly based on 
register data are lower (only 4-54 per 100 000), probably reflecting that many 
cases of FTD are not detected by the health care system, or that they receive 
other diagnoses than FTD
42, 78
. One explanation for this relatively high 
prevalence in the present study may be that bvFTD criteria were applied 
directly to the population without prior screening for global dementia. 
Another reason may be the use of comprehensive key informant interviews to 
gather information on frontal lobe symptoms and the early course of the 
disease. The diagnosis of bvFTD is probably even more underestimated in 
the oldest old, as this diagnosis is seldom considered in this age group 
40, 79
.  
 
Agreement between FTD criteria 
Despite a similar prevalence using different criteria, the agreement between 
criteria was only low to moderate. Among those with bvFTD according to the 
FTDC, only 27% had a diagnosis according to FTLD-CC, and 35% 
according to LMRC (with kappa values 0.30-0.42). The LMRC and FTLD-
CC had an overlap of only 19-21%, with a kappa of 0.20. Thus, these criteria 
captured to a large extent different individuals. The FTLD-CC diagnosed 
somewhat fewer cases than FTDC, in line with suggestions that these criteria 
are more rigid
65
. Furthermore, almost all cases diagnosed with FTLD-CC, a 
large majority of those with FTDC, but only less than half of those diagnosed 
with LMRC fulfilled criteria for global dementia. One explanation may be 
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that the LMRC is more weighted towards externalized symptoms, such as 
loss of inhibition and aggressive behaviors, while the FTLD-CC is more 
weighted towards negative symptoms, such as apathy and loss of initiative, 
and the FTLD-CC may thus miss a large proportion of cases with mainly loss 
of inhibition
65
. The FTDC seems to be somewhere in-between the other 
criteria in this regard. This finding is remarkably similar to reports describing 
low concordance between different criteria for global dementia
141
.
 
 
Neuroimaging 
A large proportion of those diagnosed according to the FTDC and LMRC 
(93-100%) had moderate-severe frontal and/or temporal lobe atrophy on CT, 
which could be compared to 13% in those without frontal lobe symptoms. 
Few studies have compared the clinical criteria of bvFTD with neuroimaging 
or neuropathology. One study reported that among 137 cases with frontal 
lobe degeneration at neuropathological examination, 85% fulfilled FTDC 
criteria for possible bvFTD and 53% fulfilled FTLD-CC criteria
25
. No 
previous studies have directly compared FTD criteria with MRI or CT in the 
setting of a population study. However, reports from memory clinics show 
that the proportion of patients with clinically diagnosed bvFTD who have 
frontal and/or temporal atrophy on neuroimaging ranges from 50 to 95% 
25, 
142-145
. 
 
Among those with moderate-severe frontal lobe atrophy on CT, 85 
individuals did not have frontal lobe symptoms as defined by any of the three 
criteria sets. Only 12% of those had other dementias. One explanation for this 
result may be that cortical thinning of the frontal lobes is also found in 
normal aging
146
, and in these cases may not lead to detectable frontal lobe 
symptoms. In addition, we cannot exclude the possibility that prior head 
trauma may partially explain the presence of frontal and/or temporal lobe 
atrophy in non-demented individuals
147
.
  
Furthermore, it has to be emphasized 
that neuroimaging is a supportive, but not mandatory diagnostic feature of all 
FTD criteria. Thus, these criteria allow a diagnosis of possible bvFTD in the 
absence of neuroimaging. However, the high correlation between frontal 
and/or temporal lobe atrophy and bvFTD according to FTDC and LMRC in 
our population study is similar to that reported from clinical studies and lends 
support for the validity of our diagnoses. 
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Risk factors 
History of alcohol abuse, head trauma, stroke and/or TIA, hypothyroidism, 
severe white matter lesions on CT of the brain and being divorced were 
associated with bvFTD in this population-based nested case-control study. 
Alcohol abuse and being divorced were associated with bvFTD in 
comparison to both control groups. Hypothyroidism was associated with 
bvFTD compared to the control group with dementia, and there was trend for 
an association (p=0.055) in comparison to the control group without 
dementia. Both head trauma
88, 89
, and hypothyroidism 
88, 90
 have previously 
been related to bvFTD in clinic-based case-control studies.  
It needs to be emphasized that this was an exploratory study, which examined 
a large number of potential risk factors. It is thus possible that some 
associations were found by chance. However, most of the findings could be 
considered as biologically plausible, and we believe that the exploratory 
approach is reasonable considering present knowledge regarding non-genetic 
risk factors in bvFTD.  
 
It is difficult to compare our study with previous case-control studies as both 
cases and controls in our study were recruited from the same general 
population, whereas previous case-control studies recruited cases from 
patient samples, and controls from other samples. Two of the previous 
studies used cognitively intact controls
88, 90
, while the third had controls with 
dementias other than FTD 
89
. The mean age of participants was also lower 
than in our study (64, 70 and 71 years versus 87 years) 
88-90
. 
 
Despite these differences, two of the previous case-controls studies and our 
study found that head trauma increased odds for bvFTD
88, 89
. Head trauma 
has also been identified as a risk factor for Alzheimer’s disease 148. The 
frontal lobes are particularly vulnerable to trauma, although the pathogenic 
mechanisms leading to bvFTD remain to be elucidated
149, 150
. Mutations 
leading to loss of function in the progranulin gene are among the known 
genetic causes of FTD 
151
, and it has been suggested that head trauma may 
reduce CNS levels of progranulin, thus increasing the risk for FTD 
152
.  
A potential pathway is shown in figure 9; based on research with PGRN-
deficient mice, it has been suggested that low progranulin levels may lead to 
neurodegeneration by disrupting the kinetics of programmed cell death
153
. 
Also, a study has shown that the brains of PGRN-deficient mice exhibit an 
exaggerated inflammatory response after infection, compared to wild-type 
mice
154
.   
Furthermore, studies have also suggested that head trauma may be linked 
with abnormal aggregation of tau and β-amyloid 155, 156. 
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Figure 10. Potential relationship between head trauma, progranulin 
and behavior variant frontotemporal dementia (bvFTD). 
 
 
 
 
This study found that alcohol abuse was related to increased risk of bvFTD 
compared to both controls with and without dementia, while light-moderate 
consumption was related to a decreased risk. A similar U-shaped association 
has been reported for dementia and Alzheimer’s disease157, 158. However, two 
of the previous studies on FTD that examined measures of alcohol 
consumption found no association with alcohol abuse
88, 89
, but one of these 
studies included individuals with alcohol-related dementia in the control 
group
89
.  
Severe alcohol abuse is known to lead to neurodegeneration, and up to 75% 
of chronic alcoholics have significant degenerative changes according to 
postmortem studies
159
. This degeneration primarily affects the frontal lobes 
and cerebellum
160-162
, and alcohol-related dementia frequently presents with 
frontal lobe symptoms 
163
. Moreover, older individuals with alcoholism have 
been shown to have to greater gray matter deficits (on MRI) in the prefrontal 
and frontal regions compared younger individuals with alcoholism
164
. 
Alcohol abuse is also associated with cognitive impairment, especially 
executive dysfunction
162
. In summary, alcohol abuse often leads to frontal 
dysfunction and it can cause structural damage in the frontal lobes and 
associated circuits, both in grey and white matter
165
.   
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Furthermore, alcohol abuse is known to influence the exposure to other 
potential risk factors, such as head trauma
161
, and exacerbate hypertension 
and diabetes mellitus
159
. Thus, there exist numerous pathways through which 
alcohol abuse could influence the development of bvFTD. 
 
This study found an association with hypothyroidism when comparing cases 
to controls without dementia, and a trend compared to controls with 
dementia. It has long been recognized that overt hypo- and hyperthyroidism 
can be accompanied by dementia symptoms that are reversible with 
treatment
166
. The association of hypothyroidism with non-FTD dementias has 
been studied in population studies; in the Framingham study, low and high 
thyrotropin levels were associated with an increased risk of AD in women
166
. 
However, another population study found no association with mild cognitive 
impairment (MCI)
167
. A previous study among elderly patients with 
neuropsychiatric disorders found that thyroid hormone abnormalities were 
common in FTD
168
 and two of the previous case-control studies on FTD 
found trends for associations with thyroid disease
88, 90
. Potential pathogenic 
mechanisms leading to bvFTD remain to be elucidated, but it has been 
suggested that thyroid hormone abnormalities may influence tau pathology 
and thus contribute to the risk for bvFTD
88, 90, 169
. Furthermore, 
hypothyroidism may influence vascular risk factors. Overt hypothyroidism 
frequently lead to hypercholesterolemia
170 
and subclinical hypothyroidism 
increases LDL and lowers HDL
170
, although the clinical significance of  this 
remains disputed
171
. Hypothyroidism can also lead to or aggravate 
hypertension and heart failure
172
, which in turn may have deleterious effects 
on cognitive function.  
We also found a trend for an association with a history of shingles (rash 
caused by the varicella-zoster virus [VZV]), a finding that has not previously 
been reported for FTD. It is known that patients with previous VZV 
encephalitis may develop long-term cognitive impairment
173, 174
, but no 
participant had a history of neuroinfectious disorder (including encephalitis) 
according to the Hospital Discharge Register. Potentially, activation of the 
varicella-zoster virus could influence FTD development through increased 
microglial activation (figure 10). However, the implications of this finding 
remain unclear, waiting further study and possible confirmation. 
 
Stroke and/or TIA and severe white matter lesions on CT of the brain were 
associated with bvFTD when cases were compared to normal controls, 
despite that frontal lobe symptoms evolving in connection with a stroke was 
an exclusion criteria according to FTDC. One previous case-control study 
found a trend for a negative association with stroke/TIA
89
 and one found no 
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association with stroke/TIA
88
. Studies on FTD neuropathology in younger 
samples have found associations with white matter damage 
175
, but not with 
other cerebrovascular pathology 
176
. It has been suggested that white matter 
damage in bvFTD represents secondary effects of neuronal degeneration, and 
not a primary vascular lesion
177
. However, these neuropathological studies 
included mainly patients with early-onset FTD 
175, 176
, and other factors, such 
as vascular pathology, might influence the development of late-onset FTD. It 
is known that mixed pathologies (i.e. Alzheimer’s disease and vascular 
pathology) become more prevalent as a cause of dementia with increasing 
age 
178, 179
, and this may also be true for bvFTD. 
One previous study found a negative association between bvFTD and 
cardiovascular disorders
89
, which we could not confirm. This previous study 
that found a negative association between FTD and cardiovascular disease 
included patients with vascular dementia in the control group, and these 
patients had a high prevalence of cardiovascular disease
89
. One previous 
study found an association with diabetes mellitus
90
, which we could not 
confirm. Family history of dementia was not associated with bvFTD, whereas 
a high proportion of early-onset FTD has a positive family history
180
. This 
suggests that genetic factors may be less important in late-onset than in early-
onset bvFTD. Furthermore, the Apolipoprotein E ε4 allele was not associated 
with bvFTD, in line with most previous studies 
181
.  
Cross-sectionally, major depression (compared to controls without dementia) 
was associated with bvFTD. There was also a trend for anxiety disorders to 
be associated with bvFTD (compared to controls with dementia). It is likely 
that these findings are secondary to the disorder itself, which is further 
supported by the finding that depression earlier in life was not associated 
with bvFTD. Psychiatric manifestations often occur early, with dysthymia 
being present in one third of patients with FTD at initial presentation
32
, and 
anxiety being more common in FTD than in AD
33, 100
. Psychotic symptoms 
were rare among bvFTD cases in our study, in line with most previous 
studies
182
. 
The finding that bvFTD cases were more likely than both control groups to 
be divorced may reflect the great caregiver burden associated with bvFTD
183, 
184
. 
 
 
In summary, these findings suggest that the development of late-life bvFTD 
may be influenced by factors with such as alcohol abuse, head trauma, stroke 
and hypothyroidism. Late-life bvFTD might to a lesser degree be due to 
genetic factors than early-onset bvFTD. This might also explain the higher 
prevalence of bvFTD after age 80, as different risk factors might have time 
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emerge during a long life and have an additive effect on the development of 
bvFTD (figure 10). However, it must be emphasized that the methods 
employed in this study do not allow for any determination of causality with 
regards to these factors, and can only give suggestions for further research 
into the pathogenic mechanisms behind FTD.  
 
 
 
 
Figure 11. Hypothetical pathways for the development of (A) early-onset behavioral 
variant frontotemporal dementia (bvFTD) and (B) late-onset bvFTD. 
 
 
Furthermore, the impact of preventive interventions on FTD, such as life-
style interventions, is not known. Higher education has been associated with 
higher levels of late-life cognition, and might delay the development of 
cognitive impairment
185
. However, this might not be true for FTD, as a study 
from Brescia, Italy has found that individuals with FTD generally had higher 
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levels of education than individuals with AD
186
. Still, the findings in the 
present study suggest that some potential risk factors might be amenable to 
preventive interventions, i.e. stroke, hypothyroidism and alcohol abuse.  
 
Mortality 
In a population-based sample of 70-95-year-olds, bvFTD was associated with 
a higher risk of death than non-FTD dementias, AD and no dementia, and a 
trend towards a higher risk of death compared to VAD. These findings hold 
true both when investigating time from examination and time from symptom 
onset to death, and when controlling for potential confounders. The 
difference in survival times between bvFTD and the other dementias was 
apparent after the age of 80 years. Depending on age at examination, 
individuals with bvFTD had from 2 to 7 years less life expectancy than 
individuals without dementia. 
Dementia disorders are suggested to be one of the major killers among the 
oldest old
187
. The findings in this study suggest that bvFTD is associated with 
even higher mortality than other dementias. Some previous studies suggested 
that individuals with bvFTD progress faster to death than patients with AD 
93
, 
but other studies have found similar survival times for these disorders
97
. 
These findings are in line with a recent study from the Swedish Dementia 
Registry which reported that FTD had the highest risk of death among all 
dementia diagnoses
188
. The higher risk of death in bvFTD compared to other 
dementias may reflect a more aggressive neurodegenerative process than in 
other dementias leading to early dysregulation of blood pressure, respiration 
and swallowing
100
. In line with this, it was reported that FTD is associated 
with higher CSF levels of neurofilament light (NFL) 
189
, known to correlate 
with damage to subcortical structures
190
, than both AD and VAD. However, 
bvFTD encompasses a wide range of behavioral and psychological symptoms 
(BPSD) that are also common in other dementia disorders
191
. Studies of 
BPSD in AD have reported that individuals with severe behavioral or 
affective/apathetic symptoms have shorter survival times than individuals 
with minimal behavioral symptoms
192
. Thus, the presence of behavioral 
symptoms might in itself be a marker of increased mortality.  
In conclusion, a diagnosis of bvFTD in this population-based sample of older 
adults was associated with a higher risk of death than a diagnosis of other 
dementias. This suggests that late-life bvFTD has a more aggressive course 
than other late-life dementias.  
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Considerations common to Papers I-IV 
Among the strengths of this study is the large population-based study, the 
comprehensive examinations including interviews with key informants, and 
that cases and controls were taken from the same population. Furthermore, all 
individuals were examined with a wide range of psychiatric and neurological 
variables, including those described in the new FTDC criteria, the FTLD-CC 
and the LMRC. Therefore, it was possible to design symptom algorithms, 
even though some data were collected before the criteria were published. A 
further advantage is that it was possible to examine the different criteria in 
relation to frontal and/or temporal lobe atrophy on CT. However, there are 
also some limitations. 
First, the validity of a clinical diagnosis of bvFTD without neuropathological 
confirmation could be questioned. However, the correlation between our 
diagnosis of bvFTD and frontal atrophy on CT was high (80%) and the 
correlation between bvFTD according to FTDC criteria and neuropathology 
has also been found to be high
25
. Furthermore, it is important to emphasize, 
that the bvFTD diagnosis presented in this dissertation refers to a possible 
bvFTD, as it is outlined in the FTDC criteria
25
. Even with a high correlation 
with neuroimaging, it is impossible to exclude that some of the persons with 
bvFTD might have had atypical Alzheimer’s disease (AD), argyrophilic grain 
disease or some other neurodegenerative or vascular disease. This distinction 
may be especially difficult to make at very high ages, where AD is common. 
Moreover, the prevalence of frontal-predominant AD has been difficult to 
establish
193
. Previous studies report that frontal-predominant AD pathology is 
found in up to 10% of clinical FTD cases
194, 195
.  
Second, FTD among older adults may occasionally present as an amnesic 
state and neuroimaging in these cases often shows focal hippocampal 
sclerosis
80
. The LMRC and FTLD-CC do not permit a diagnosis of FTD in 
these cases. The FTDC permits a diagnosis of bvFTD in individuals who 
present with an amnesic state if psychometric testing is compatible is with 
FTD, i.e. if the psychometric tests show executive deficits with relative 
sparing of episodic memory and visuospatial functions
25
. This criterion could 
thus not be applied in our cross-sectional study which uses retrospective 
information to elucidate the early course of the disorder. Some FTD cases 
according to FTDC may thus have been missed, leading to underestimation 
of the prevalence of bvFTD. Furthermore, if this criterion had been applied, 
the correlation between FTDC and the other criteria would have been even 
lower. Unfortunately, the neuroimaging technique (CT) employed in this 
study did not allow us to detect hippocampal sclerosis.  
Third, some results are based on retrospective information from key 
informants, which may lead to recall bias. Key informants of affected 
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individuals may remember more previous events than relatives of controls, 
leading to false positive results. On the other hand, key informants of such 
old individuals as in our study may not know about or remember events 
occurring decades ago, leading to false negative results.  
Fourth, due to the study design, we were not able to study other types of FTD 
such as semantic dementia and primary progressive aphasia. Fifth, the 
proportion of women in our study was high (80%), partly because our study 
included samples from the Prospective Population Study of Women. 
However, the proportion of women in the Swedish general population over 
age 70 was always higher than the proportion of men during the period when 
the data was collected (1986-2001), especially for those older than 85 years 
196
. Sixth, we had a larger refusal rate for CT in those with bvFTD than in the 
rest of the population, resulting in few individuals in that substudy. The 
results of neuroimaging should therefore be taken with caution.  
Finally, the study was conducted over a long time span with pooling of 
several different population studies. However, all studies included the same 
protocol and were performed by the same research group, and the last author 
was PI of all studies. Furthermore, evaluation of data and diagnosis of bvFTD 
were done by the same neuropsychiatrists irrespective of year of examination. 
Still, we cannot exclude the possibility that examination procedure changed 
during this period. 
 
Considerations specific to Paper III (Risk Factors) 
First, due to the cross-sectional design, we cannot make any inferences 
regarding direction of associations. For example, the neurotoxic action of 
alcohol may lead to degenerative changes in the frontal lobes, but frontal lobe 
dysfunction may also lead to increased alcohol intake
160
. Furthermore, 
alcohol abuse increases the risk of being exposed to other detrimental factors 
(e.g. smoking, head trauma and socioeconomic problems). However, the low 
incidence of bvFTD makes it difficult to study risk factors for bvFTD in 
longitudinal studies. Second, there is a possibility of false positive findings 
due to multiple comparisons. We did not control for multiple comparisons as 
this may give rise to false negative results. One way to treat this problem is to 
make no adjustments for the number of comparisons but to give information 
on how many comparisons have been made and to emphasize that any new 
findings should be biologically plausible and considered only suggestive until 
further confirmed 
197
. Third, it needs to be re-emphasized that some results 
Frontotemporal dementia in late life 
58 
 
are based on retrospective information from key informants, which may lead 
to recall bias. Key informants of cases may remember more previous events 
than relatives of controls, leading to false positive results. On the other hand, 
key informants may not know about or remember events occurring decades 
ago, leading to false negative results. Fourth, the quality of diagnosis from 
hospital discharge registers could vary. Low validity of these sources might 
lead to false negative results. Fifth, the age of our sample is considerably 
higher than in previous case-controls studies of bvFTD, and other risk factors 
might be involved in this older population than in younger age groups. Sixth, 
the study was conducted over a long time span with pooling of several 
different population studies. Thus, we can however not exclude that the effect 
of different risk factors might have been influenced by time-trends. Finally, 
the number of individuals in some of the groups was rather small. Negative 
findings should therefore be taken cautiously due to lack of statistical power. 
 
Considerations specific to Paper IV (Mortality) 
Among the strength of this paper is the use of the Swedish Health and 
Welfare Statistical Database for Cause of Death, which is known to be almost 
complete regarding mortality data 
126
.  
 
There are also some limitations. First, the data were collected over a long 
period of time using several different population studies. During this time, 
survival increased in the general population. Controlling for birth cohort did 
however not change the results. We cannot, however, exclude the possibility 
that secular trends in the frequency of FTD and survival might have 
influenced the results.  
Second, only few participants among those aged 70-79 years had bvFTD. We 
could therefore not make any conclusion about mortality and survival in 
bvFTD in this age group. Third, response rates were around 65-70%. 
Responders and non-responders differed with regards to mortality, mainly 
explained by higher mortality among 70-79-year-old non-responders. Thus, it 
is possible that responders and non-responders also differed regarding frontal 
lobe symptoms.  
Fourth, individuals with bvFTD were more likely to have a history of 
stroke/TIA than individuals with no dementia. However, adjusting for stroke 
did not influence the results. Fifth, the validity of death certificates could be 
questioned. It has been suggested that up to one third of death certificates are 
likely to be incorrect 
198
, maybe explained in part by declining autopsy rates.   
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Finally, part of the diagnostic criteria and estimation of age at onset in this 
study required retrospective information from key informants. This was 
necessary to elucidate early symptoms and course of symptom development, 
and age of onset. Although information from key informants may be 
uncertain, it is also used in clinical studies to determine age of onset. 
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CONCLUSIONS 
The prevalence of bvFTD in this elderly population was higher than 
expected, especially among the oldest old. The correlation between the 
different criteria for bvFTD was low, suggesting that further development of 
research criteria is required. Both the FTDC and the LMRC had a high 
correlation with frontal and/or temporal lobe atrophy, but only a moderate 
agreement with each other, suggesting that both FTDC and LMRC could be 
underestimating the prevalence of bvFTD. This suggests that any modified 
bvFTD criteria should allow for a more flexible combination of frontal lobe 
symptoms than is possible in the current FTD criteria, as it is important to 
capture all presentations of FTD. Furthermore, as potential treatments for 
FTD (aimed at increasing progranulin levels) may become available in the 
foreseeable future
199
, it becomes crucial to accurately diagnose FTD, and to 
do so as early in the course of the disorder as possible.    
It is important to identify possible non-genetic risk factors for FTD, as up to 
50% of FTD cases may be sporadic. History of alcohol abuse, stroke/TIA, 
head trauma and hypothyroidism were associated with increased odds of 
bvFTD in this study. These findings have implications for future studies into 
the etiology of sporadic bvFTD, and ultimately, for prevention among older 
adults. 
In conclusion, a diagnosis of bvFTD in this population-based sample of older 
adults was associated with a higher risk of death than a diagnosis of other 
dementias. This suggests that late-life bvFTD has a more aggressive course 
than other late-life dementias, a finding that can be used to inform relatives, 
care givers and health care providers. These findings have also implications 
for future studies into the clinical course of sporadic bvFTD.  
 
In 1926, Onari and Spatz wrote: “We are convinced that Pick’s disease is not 
extremely rare, but often both the clinician and the anatomist do not 
recognize it, because not enough focus is directed towards it” 8.  In some way, 
these words hold true, even today. The findings presented in this dissertation 
point to the need for increased awareness of bvFTD among older adults, and 
for further research in this field.  
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FUTURE PERSPECTIVES 
The longitudinal design of the studies among older adults in Gothenburg 
allows for further investigations regarding different facets of FTD. This 
design makes it possible to study secular trends in the prevalence of bvFTD 
and to prospectively study the impact of factors such as alcohol consumption, 
thyroid function tests (TSH, free T4), medications affecting thyroid function, 
head trauma, cerebrovascular disease and changes in socio-economic status.  
Also, other potential risk factors could be examined, such as physical 
inactivity, dietary aspects, sleep, breastfeeding, female reproductive health, 
oral health and the impact of early and/or mid-life stress. Furthermore, future 
studies will also give an opportunity to examine secular trends in the 
mortality of FTD. 
Future studies could give important insights into the etiology and course of 
bvFTD, and could ultimately inform diagnostic guidelines and preventive 
strategies. 
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